Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Section 4 of 6

Clinical evidence

396 evidence topics · 52 sources

Study summaries

ONWARD1

Objective
Location and study date
Country removed from the ClinicalTrials.gov record
FieldQuoted record
Removed location countries (removedCountries)“Belgium”
Study design
Eligibility criteria
Treatment
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using PASI 75 and sPGA 0/1 response as the co-primary endpoints
Secondary outcomes in the ClinicalTrials.gov record
Secondary outcome measureMeasure descriptionTime frame
“To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast”“Proportion of participants achieving of ≥90% or 100% reduction in PASI”“24 weeks”
“To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast”“Proportion of participants achieving of ≥75% reduction in PASI”“24 weeks”
“To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast”“Proportion of participants achieving a score of 0 or 1 on sPGA”“24 weeks”
“To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast”“Change from baseline in %BSA”“24 weeks”
“To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast.”“Proportion of participants achieving a score of 0 or 1 on ssPGA”“24 weeks”
“To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast”“Proportion of participants achieving a score of 0”“24 weeks”
“To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast”“Proportion of participants achieving a score of 0 or 1”“24 weeks”
“To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo”“Change from baseline in Pruritus NRS”“24 weeks”
“Proportion of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)”“Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)”“24 weeks”
“To characterize the pharmacokinetics of ESK-001”“Maximum [Cmax] and minimum [Cmin] plasma concentration”“24 weeks”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics
Baseline demographics and disease characteristics by arm in ONWARD1
CharacteristicEnvudeucitinib 40 mg BID, n = 459Placebo, n = 230Apremilast 30 mg BID, n = 223
Age, years, mean (SD)“49.1 (13.4)”“49.2 (13.3)”“47.7 (11.8)”
Age group, ≥65 years, n (%)“61 (13.3)”“27 (11.7)”“15 (6.7)”
Sex, male, n (%)“300 (65.4)”“156 (67.8)”“152 (68.2)”
Race, White, n (%)“358 (78.0)”“182 (79.1)”“177 (79.4)”
Race, Asian, n (%)“68 (14.8)”“28 (12.2)”“30 (13.5)”
Race, other, n (%)“33 (7.2)”“20 (8.7)”“16 (7.2)”
Weight, kg, mean (SD)“90.4 (24.0)”“91.0 (24.3)”“88.9 (21.0)”
BMI, kg/m2, mean (SD)“30.6 (7.2)”“30.6 (7.2)”“29.8 (6.5)”
Duration of disease, years, mean (SD)“19.9 (13.5)”“19.5 (13.3)”“17.2 (11.8)”
PASI, mean (SD)“20.4 (8.0)”“19.9 (7.5)”“20.3 (6.9)”
sPGA of 4, n (%)“129 (28.1)”“57 (24.8)”“61 (27.4)”
BSA % affected, mean (SD)“25.8 (15.8)”“26.2 (16.0)”“25.2 (14.9)”
DLQI, mean (SD)“10.6 (6.5)”“10.1 (6.7)”“10.8 (6.8)”
Worst pruritus NRS, mean (SD)“6.1 (2.7)”“6.0 (2.7)”“6.3 (2.6)”
Prior systemic psoriasis treatment, n (%)“221 (48.1)”“113 (49.1)”“107 (48.0)”
Baseline itch and scalp involvement by arm in ONWARD1
CharacteristicEnvudeucitinib 40 mg BID, N = 459Placebo, N = 230Apremilast 30 mg BID, N = 223
Worst pruritus NRS ≥1, n (%)“420 (91.5)”“210 (91.3)”“210 (94.2)”
Worst pruritus NRS ≥4, n (%)“353 (76.9)”“175 (76.1)”“176 (78.9)”
ss-PGA ≥3, n“274”“135”“150”
Worst pruritus NRS ≥4 and ss-PGA ≥3, n (%)“213 (77.7)”“102 (75.6)”“124 (82.7)”
Efficacy results
Co-primary and secondary endpoint results of ONWARD1 and ONWARD2 at topline

“Envudeucitinib met all primary and secondary endpoints with high statistical significance in ONWARD1 and ONWARD2.” (opens the source at this quote in a new tab)

“In each of these trials, envudeucitinib achieved superior skin clearance compared with placebo (p < 0.0001) on the co-primary endpoints of Psoriasis Area and Severity Index (PASI) 75 and static Physician’s Global Assessment (sPGA) 0/1 at Week 16.” (opens the source at this quote in a new tab)

“On average across both ONWARD1 and ONWARD2, 74% of patients achieved PASI 75 and 59% of patients achieved sPGA 0/1, with responses deepening over time.” (opens the source at this quote in a new tab)

“In addition, the placebo-adjusted response rates for the co-primary endpoints were consistent between the two trials.” (opens the source at this quote in a new tab)

“At Week 24, on the higher hurdle skin clearance measures, approximately 65% of patients achieved PASI 90, and more than 40% achieved PASI 100, on average across both trials.” (opens the source at this quote in a new tab)

“Rapid responses were observed, with clear separation from placebo on PASI 90 as early as Week 4.” (opens the source at this quote in a new tab)

“Envudeucitinib also achieved superior skin clearance compared with apremilast in each trial (p<0.0001) on all PASI endpoints at Week 24.” (opens the source at this quote in a new tab)

PASI 75, PASI 90, and PASI 100 response rates at week 16 in ONWARD1
Week 16 response, %Envudeucitinib 40 mg BID, n = 459Placebo, n = 230Apremilast 30 mg BID, n = 223
PASI 75 (co-primary endpoint)“76.5”“18.7”“44.4”
PASI 90“59.9”“4.8”“21.5”
PASI 100“29.4”“0.9”“4.0”
PASI 75, PASI 90, and PASI 100 response rates at week 24 in ONWARD1
Week 24 response, %Envudeucitinib 40 mg BID, n = 459Apremilast 30 mg BID, n = 223
PASI 75“78.6”“46.2”
PASI 90“68.0”“25.6”
PASI 100“41.0”“8.5”
Treat-to-target PASI and BSA thresholds in a post hoc analysis of ONWARD1 and ONWARD2

“To evaluate the achievement of clinically relevant treat-to-target thresholds for PASI and BSA in a post hoc analysis of ONWARD1 and ONWARD2” (opens the source at this quote in a new tab)

“Absolute PASI thresholds (0, ≤1, and ≤3) and BSA (≤3% and ≤1%) were calculated post hoc and assessed at Week 16 (vs placebo and apremilast) and Week 24 (vs apremilast)” (opens the source at this quote in a new tab)

“Patients who discontinued or had missing data were imputed as nonresponders” (opens the source at this quote in a new tab)

“Least squares (LS) means and corresponding 95% CIs for percent change from baseline in PASI total score were estimated using a mixed model with repeated measures (MMRM) with modified baseline observation carried forward (mBOCF) imputation; nominal P-values for treatment comparisons are presented at Weeks 16 and 24” (opens the source at this quote in a new tab)

“At Week 16, significantly more patients treated with envudeucitinib achieved clinically meaningful PASI treatment targets (Figure 3) and BSA treatment targets (Figure 4) vs placebo and apremilast” (opens the source at this quote in a new tab)

“Responses continued to improve through Week 24 for all thresholds” (opens the source at this quote in a new tab)

“Improvement in PASI from baseline with envudeucitinib was evident at Week 2 (Figure 6)” (opens the source at this quote in a new tab)

“Patients receiving envudeucitinib met stringent treat-to-target thresholds associated with disease control, with response rates increasing from Weeks 16 to 24” (opens the source at this quote in a new tab)

Efficacy by prior biologic exposure or body weight

No evidence found.

Health-related quality of life and patient-reported outcomes
Itch response at week 2, itch resolution at week 16, and responses through week 24 in ONWARD1 and ONWARD2
Safety results
Pooled ONWARD1 and ONWARD2 adverse events through weeks 16 and 24
Outcome, n (%)Week 16: envudeucitinib 40 mg BID, n = 890Week 16: placebo, n = 441Week 16: apremilast 30 mg BID, n = 438Week 24: envudeucitinib 40 mg BID only, n = 890Week 24: placebo to envudeucitinib 40 mg BID, n = 390Week 24: overall envudeucitinib 40 mg BID, n = 1280Week 24: apremilast 30 mg BID, n = 438
At least 1 TEAE“524 (58.9)”“166 (37.6)”“223 (50.9)”“563 (63.3)”“130 (33.3)”“693 (54.1)”“248 (56.6)”
At least 1 SAE“19 (2.1)”“5 (1.1)”“5 (1.1)”“24 (2.7)”“1 (0.3)”“25 (2.0)”“6 (1.4)”
TEAE leading to treatment discontinuation“30 (3.4)”“7 (1.6)”“9 (2.1)”“31 (3.5)”“4 (1.0)”“35 (2.7)”“12 (2.7)”
TEAE grade ≥3“42 (4.7)”“14 (3.2)”“18 (4.1)”“48 (5.4)”“7 (1.8)”“55 (4.3)”“23 (5.3)”
Nasopharyngitis“64 (7.2)”“21 (4.8)”“16 (3.7)”“92 (10.3)”“18 (4.6)”“110 (8.6)”“26 (5.9)”
Headache“92 (10.3)”“11 (2.5)”“40 (9.1)”“97 (10.9)”“11 (2.8)”“108 (8.4)”“42 (9.6)”
Upper respiratory tract infection“43 (4.8)”“7 (1.6)”“16 (3.7)”“57 (6.4)”“2 (0.5)”“59 (4.6)”“21 (4.8)”
Acne“53 (6.0)”“3 (0.7)”“3 (0.7)”“60 (6.7)”“17 (4.4)”“77 (6.0)”“3 (0.7)”
Nausea“20 (2.2)”“4 (0.9)”“23 (5.3)”“20 (2.2)”“0”“20 (1.6)”“23 (5.3)”
Diarrhea“14 (1.6)”“11 (2.5)”“36 (8.2)”“16 (1.8)”“1 (0.3)”“17 (1.3)”“36 (8.2)”
Herpes zoster and creatine phosphokinase elevations

No evidence found.

Study limitations
Summary
  • ONWARD1 results are available from company press releases, a company webcast presentation, and congress materials (Blauvelt et al., Hawkes et al., Ehst et al.). The ClinicalTrials.gov record reads “No Results Posted” and records a certification/extension first submitted on 2026-08-06.
  • Placebo control lasted 16 weeks, after which placebo participants rolled over to envudeucitinib; the week 24 PASI results compare envudeucitinib with apremilast alone.
  • The report holds no participant disposition by arm, no efficacy by prior biologic exposure or body weight, and no herpes zoster or creatine phosphokinase data. Safety, itch, and DLQI results are reported only for ONWARD1 and ONWARD2 pooled.
  • The sources differ on itch: the congress presentation places the mean decrease of more than 4 points in worst pruritus NRS by week 12 and a press release by week 16; at week 16, NRS 0 is reported as over one-third (itch poster) and about 40% (press release), and NRS 0/1 as more than half and approximately 60%.
  • Prior treatment is reported on different measures: prior systemic treatment by arm in 221 (48.1%), 113 (49.1%), and 107 (48.0%) participants (congress presentation), and, averaged across both trials, “Over 40% prior systemic use” and approximately 25% prior biologic use (webcast presentation). The report holds no prior biologic use by arm.
  • The itch analysis reports nominal P-values, and the PASI and BSA treat-to-target thresholds were calculated post hoc.
  • Eligibility excluded participants with lack of clinical response to a TYK2, IL-12, or IL-23 targeted treatment and those with recent or recurrent herpes zoster or herpes simplex infection.
  • The webcast presentation lists Belgium among the countries of study ESK-001-016, and the ClinicalTrials.gov API record for NCT06586112 lists Belgium as a removed location country.

ONWARD2

Objective
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
FieldQuoted record
Study start (actual)“2024-08-20”
Primary completion (actual)“2025-09-23”
Study completion (actual)“2025-12-18”
First submitted“2024-09-07”
Last update posted“2026-10-28”
Completion dates estimated at registration, September 2024, superseded in June 2025
Results posting status and certification date in the ClinicalTrials.gov record
FieldQuoted record
Results“No Results Posted”
Certification/extension first submitted“2026-08-06”
Study design
Eligibility criteria
Washout for IL-12 and IL-23 agents at registration, September 2024, superseded in October 2024
Treatment
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using PASI 75 and sPGA 0/1 response as the co-primary endpoints
Secondary outcomes in the ClinicalTrials.gov record
Secondary outcome measureMeasure descriptionTime frame
“To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast”“Proportion of patients achieving of ≥90% or 100% reduction in PASI”“24 weeks”
“To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast”“Proportion of patients achieving of ≥75% reduction in PASI”“24 weeks”
“To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast”“Proportion of patients achieving a score of 0 or 1 on sPGA”“24 weeks”
“To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast”“Change from baseline in %BSA”“24 weeks”
“To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast”“Proportion of patients achieving a score of 0 or 1 on ssPGA”“24 weeks”
“To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast”“Proportion of patients achieving a score of 0”“24 weeks”
“To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast”“Proportion of patients achieving a score of 0 or 1”“24 weeks”
“To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo”“Change from baseline in Pruritus NRS (scale is from 0 (no pain) to 10 (severe pain)).”“24 weeks”
“Proportion of patients with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)”“Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)”“24 weeks”
“To characterize the pharmacokinetics of ESK-001”“Maximum [Cmax] and minimum [Cmin] plasma concentration”“24 weeks”
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment at registration
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics
Baseline demographics and disease characteristics by arm in ONWARD2
CharacteristicEnvudeucitinib 40 mg BID, n = 433Placebo, n = 211Apremilast 30 mg BID, n = 215
Age, years, mean (SD)“48.3 (13.1)”“49.5 (13.3)”“48.0 (12.8)”
Age group, ≥65 years, n (%)“51 (11.8)”“28 (13.3)”“20 (9.3)”
Sex, male, n (%)“283 (65.4)”“135 (64.0)”“135 (62.8)”
Race, White, n (%)“388 (89.6)”“181 (85.8)”“193 (89.8)”
Race, Asian, n (%)“10 (2.3)”“10 (4.7)”“7 (3.3)”
Race, other, n (%)“35 (8.1)”“20 (9.5)”“15 (7.0)”
Weight, kg, mean (SD)“92.3 (23.8)”“91.1 (23.1)”“90.8 (19.9)”
BMI, kg/m2, mean (SD)“31.2 (7.8)”“31.1 (7.3)”“30.9 (5.9)”
Duration of disease, years, mean (SD)“19.0 (13.5)”“20.2 (14.5)”“18.7 (14.5)”
PASI, mean (SD)“20.6 (8.3)”“21.8 (9.0)”“20.4 (8.4)”
sPGA of 4, n (%)“131 (30.3)”“70 (33.2)”“53 (24.7)”
BSA % affected, mean (SD)“25.2 (14.7)”“27.3 (16.7)”“25.8 (14.1)”
DLQI, mean (SD)“10.8 (7.0)”“10.8 (6.8)”“9.7 (7.1)”
Worst pruritus NRS, mean (SD)“6.4 (2.6)”“6.4 (2.4)”“6.0 (2.7)”
Prior systemic psoriasis treatment, n (%)“213 (49.2)”“105 (49.8)”“102 (47.4)”
Baseline itch and scalp involvement by arm in ONWARD2
CharacteristicEnvudeucitinib 40 mg BID, N = 433Placebo, N = 211Apremilast 30 mg BID, N = 215
Worst pruritus NRS ≥1, n (%)“400 (92.4)”“200 (94.8)”“199 (92.6)”
Worst pruritus NRS ≥4, n (%)“345 (79.7)”“180 (85.3)”“170 (79.1)”
ss-PGA ≥3, n“285”“140”“134”
Worst pruritus NRS ≥4 and ss-PGA ≥3, n (%)“231 (81.1)”“122 (87.1)”“108 (80.6)”
Efficacy results
PASI 75, PASI 90, and PASI 100 response rates at week 16 in ONWARD2
Week 16 response, %Envudeucitinib 40 mg BID, n = 433Placebo, n = 211Apremilast 30 mg BID, n = 215
PASI 75 (co-primary endpoint)“70.4”“13.7”“38.6”
PASI 90“53.1”“4.3”“20.9”
PASI 100“27.7”“0.9”“7.9”
PASI 75, PASI 90, and PASI 100 response rates at week 24 in ONWARD2
Week 24 response, %Envudeucitinib 40 mg BID, n = 433Apremilast 30 mg BID, n = 215
PASI 75“75.1”“43.3”
PASI 90“62.1”“25.6”
PASI 100“39.5”“13.0”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • ONWARD2-specific results are limited to baseline characteristics and PASI 75, PASI 90, and PASI 100 rates at weeks 16 and 24 in one congress presentation. The report holds no description of the ONWARD2 analysis sets, participant disposition, patient-reported outcomes, or safety for ONWARD2 alone, and no ONWARD2 sPGA 0/1 rate.
  • The ClinicalTrials.gov record gives an actual enrollment of 862 participants; the congress presentation gives arm sizes of 433, 211, and 215.
  • The ClinicalTrials.gov record reads “No Results Posted”, with a certification/extension first submitted on 2026-08-06.
  • Asian participants made up 10 (2.3%), 10 (4.7%), and 7 (3.3%) of the envudeucitinib, placebo, and apremilast arms, and White participants 388 (89.6%), 181 (85.8%), and 193 (89.8%).
  • Baseline sPGA of 4 was recorded in 131 (30.3%), 70 (33.2%), and 53 (24.7%) participants of the envudeucitinib, placebo, and apremilast arms, and mean baseline PASI was 20.6, 21.8, and 20.4.

ONWARD3

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Secondary outcomes in the ClinicalTrials.gov record
Secondary outcome measureMeasure description and time frame
“To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-75)”“Proportion of patients achieving ≥75% reduction in PASI 24, 48, 72, and 96 weeks”
“To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-90)”“Proportion of patients achieving ≥90% reduction in PASI 24, 48, 72, and 96 weeks”
“To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-100)”“Proportion of patients achieving 100% reduction in PASI 24, 48, 72, and 96 weeks”
“To assess the long-term efficacy of ESK-001 using the Static Physician's Global Assessment (sPGA 0/1)”“Proportion of patients achieving a score of 0 or 1 on sPGA 24, 48, 72, and 96 weeks”
“To assess the long-term efficacy of ESK-001 based on change in Psoriasis Area and Severity Index (PASI)”“Change in Psoriasis Area and Severity Index (PASI) from baseline assessments 24, 48, 72, and 96 weeks”
“To assess the long-term efficacy of ESK-001 based on change in Affected Body Surface Area (%BSA)”“Change in affected body surface area (%BSA) from baseline assessments 24, 48, 72, and 96 weeks”
“To characterize the loss of PASI-75 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)”“Median time to loss of PASI-75 response Week 48”
“To characterize the loss of PASI-90 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)”“Median time to loss of PASI-90 response Week 48”
“To characterize the loss of sPGA-0/1 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)”“Median time to loss of sPGA-0/1 response Week 48”
“To assess the change in quality of life (QoL) using Dermatology Life Quality Index after long-term ESK-001 administration”“Proportion of patients achieving a DLQI-0/1 score of 0 (no effect) or 1 (minimal effect) Week 24, Week 48, and Week 72”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics at ONWARD3 entry by parent-study arm
CharacteristicEnvudeucitinib then envudeucitinib (n = 773)Placebo then envudeucitinib (n = 367)Apremilast then envudeucitinib (n = 369)
Envudeucitinib exposure at start of ONWARD3, weeks“24”“8”“0”
Age, years, mean (SD)“49.6 (13.2)”“50.6 (13.3)”“49.1 (12.4)”
Duration of disease, years, mean (SD)“20.2 (13.5)”“20.1 (13.8)”“19.0 (13.0)”
Prior systemic psoriasis treatment, n (%)“395 (51.1)”“185 (50.4)”“186 (50.4)”
PASI, mean (SD)“1.9 (3.6)”“4.5 (5.5)”“6.7 (7.0)”
ss-PGA ≥3, n (%)“18 (2.3)”“21 (5.7)”“58 (15.7)”
BSA % affected, mean (SD)“3.8 (7.7)”“9.4 (12.3)”“10.7 (13.2)”
Worst pruritus NRS score, mean (SD)“1.3 (1.9)”“2.0 (2.3)”“3.1 (2.8)”
DLQI, mean (SD)“1.8 (3.1)”“2.9 (3.8)”“4.0 (4.9)”
Efficacy results
Maintenance of skin and scalp response at 48 weeks among ONWARD1 and ONWARD2 responders
EndpointAchieved response at the end of ONWARD1 and 2, nMaintained response after 24 weeks in ONWARD3 (48 weeks of total exposure), % (95% CI)
PASI 75“678”“89.8 (87.3, 92.0)”
PASI 90“575”“89.4 (86.6, 91.8)”
sPGA-0/1“584”“87.5 (84.5, 90.1)”
PASI 100“357”“80.1 (75.6, 84.1)”
sPGA-0“365”“79.5 (74.9, 83.5)”
ss-PGA-0/1, among patients with parent baseline ss-PGA ≥3“418”“89.5 (86.1, 92.2)”
Health-related quality of life and patient-reported outcomes
Maintenance of itch and DLQI response at 48 weeks among ONWARD1 and ONWARD2 responders
EndpointAchieved response at the end of ONWARD1 and 2, nMaintained response after 24 weeks in ONWARD3 (48 weeks of total exposure), % (95% CI)
At least 4-point improvement from parent baseline in NRS worst pruritus, among patients with parent baseline NRS worst score ≥4“509”“86.2 (82.9, 89.1)”
DLQI-0/1, among patients with parent baseline DLQI ≥2“497”“86.3 (83.0, 89.2)”
Safety results
Adverse events with exposure-adjusted incidence rates by parent-study arm through week 48
EventEnvudeucitinib then envudeucitinib (n = 773), n (%)EAIRPlacebo then envudeucitinib (n = 367), n (%)EAIRApremilast then envudeucitinib (n = 369), n (%)EAIR
At least 1 TEAE“521 (67.4)”“177.9”“253 (68.9)”“185.4”“268 (72.6)”“219.2”
At least 1 SAE“25 (3.2)”“4.7”“16 (4.4)”“6.3”“9 (2.4)”“3.6”
TEAEs grade ≥3“45 (5.8)”“8.6”“31 (8.4)”“12.5”“16 (4.3)”“6.5”
TEAEs leading to discontinuation“23 (3.0)”“4.3”“11 (3.0)”“4.2”“25 (6.8)”“10.1”
Related TEAEs“104 (13.5)”“21”“52 (14.2)”“21.7”“82 (22.2)”“37.9”
Nasopharyngitis“109 (14.1)”“22.2”“67 (18.3)”“28.8”“44 (11.9)”“19”
Upper respiratory tract infection“92 (11.9)”“18.4”“44 (12.0)”“18.1”“44 (11.9)”“18.7”
Influenza“34 (4.4)”“6.5”“19 (5.2)”“7.5”“17 (4.6)”“6.9”
Urinary tract infection“37 (4.8)”“7.1”“9 (2.5)”“3.5”“13 (3.5)”“5.3”
Acne“14 (1.8)”“2.6”“9 (2.5)”“3.5”“18 (4.9)”“7.5”
Study limitations
Summary
  • Results of the randomized treatment withdrawal period, which began after 24 weeks for the first 200 participants, are “data not reported” in the congress poster.
  • All participants received open-label envudeucitinib during the first 24 weeks, with no concurrent control group; regulatory guidance states that the absence of a concurrent control group makes it more difficult to assess the causality relationship between adverse events and the drug.
  • Entry required completion of week 24 of a parent trial, consent, and acceptable safety and tolerability of the drug in the parent study. The maintenance analyses are restricted to participants who had a response at entry, and the poster states that the analyses are descriptive.
  • Envudeucitinib exposure at week 48 differed by parent-study arm (48, 32, and 24 weeks), and the exposure-adjusted incidence rates are based on exposure in ONWARD3 only.
  • Week 48 PASI 90 and PASI 100 rates come from two analyses: a non-responder imputation analysis of 773 entrants (75% and 54%) and an integrated non-responder imputation analysis of 890 participants originally randomized to envudeucitinib (66% and 47%).
  • Enrollment is reported as 1680 (estimated, ClinicalTrials.gov), 1,509 entrants (press release), and 773, 367, and 369 by parent-study arm (poster).
  • The poster describes malignancies and serious infections as occurring at rates consistent with expected background rates without giving counts, and the report holds no ONWARD3 participant disposition beyond study entry.
  • The study is ongoing, with primary completion estimated for 2028-11.

STRIDE

Objective
Location and study date
Countries of trial sites in the ClinicalTrials.gov record
Study design
Eligibility criteria
Exclusion criteria on prior treatment washout and lack of response to biologic therapies in the protocol

“5. Has used topical medications/treatments that could affect psoriasis evaluation within 2 weeks of the first administration of study drug” (opens the source at this quote in a new tab)

“6. Has received phototherapy or any systemic medications/treatments that could affect psoriasis evaluation within 4 weeks of Study Day 1” (opens the source at this quote in a new tab)

“7. Has received any therapeutic agent targeted to: IL-12or IL-23 within 6 months, IL-17 within 4 months, or any TNFα inhibitor(s) within 2 months of first administration of study drug” (opens the source at this quote in a new tab)

“8. Is currently receiving or has received any systemic immunosuppressants or immunomodulatory drugs (e.g., methotrexate, cyclosporine) within 4 weeks of the first administration of study drug or 5 half-lives whichever is longer” (opens the source at this quote in a new tab)

“9. Has received agents that modulate B cells (e.g., rituximab, ocrelizumab) within 6 months of first administration of study drug” (opens the source at this quote in a new tab)

“10. Has received agents that modulate T cells (e.g., abatacept, alemtuzumab) within 3 months of first administration of study drug” (opens the source at this quote in a new tab)

“11. Has received JAK inhibitors (e.g., baricitinib, tofacitinib) or TYK2 inhibitors within 4 weeks of first administration of study drug” (opens the source at this quote in a new tab)

“12. History of lack of clinical response to any therapeutic agent targeted to IL-12, IL-17 or IL-23 (e.g., ustekinumab, risankizumab, secukinumab, ixekizumab) at approved doses after at least 3 months of treatment” (opens the source at this quote in a new tab)

“13. History of lack of clinical response, in the Investigator’s opinion, to 2 or more biologic therapies at approved doses after at least 3 months of treatment” (opens the source at this quote in a new tab)

“14. Has received any investigational agent, within 30 days or 5 half-lives (whichever is longer) of any study drug or is currently enrolled in an investigational study” (opens the source at this quote in a new tab)

Exclusion criteria on QTcF, cardiovascular disease, infections, and laboratory values in the protocol

“16. Patients with QTcF >450 msec (males) or >470 msec (females) at screening” (opens the source at this quote in a new tab)

“17. Unstable cardiovascular disease, defined as a recent clinical deterioration (e.g., unstable angina, rapid atrial fibrillation) or a cardiac hospitalization within the last 3 months” (opens the source at this quote in a new tab)

“18. Active herpes viral infection, including herpes simplex 1 and 2 and herpes zoster identified on examination and/or medical history within 2 months of administration of study drug” (opens the source at this quote in a new tab)

“19. Patients with hepatitis C virus (HCV), or hepatitis B virus (HBV) or human immunodeficiency virus (HIV) or active or inadequately treated latent tuberculosis (TB) infection at screening” (opens the source at this quote in a new tab)

“20. Has any of the following lab abnormalities:” (opens the source at this quote in a new tab)

“Absolute neutrophil count <1.5 X 10^9/L” (opens the source at this quote in a new tab)

“Hemoglobin <9 g/dL” (opens the source at this quote in a new tab)

“AST/ALT ≥2 x upper limit of normal (ULN)” (opens the source at this quote in a new tab)

“Albumin <3 g/dL” (opens the source at this quote in a new tab)

“Total bilirubin ≥2 x ULN (patients with a history of Gilbert’s syndrome are not eligible)” (opens the source at this quote in a new tab)

“Glomerular filtration rate <50 (Cockcroft and Gault method)” (opens the source at this quote in a new tab)

“22. History of serious bacterial, fungal, or viral infections that led to hospitalization and IV antibiotic treatment within 90 days prior to screening, or any recent serious infection requiring antibiotic treatment within 30 days of Study Day 1” (opens the source at this quote in a new tab)

Exclusion criteria on corticosteroid-requiring conditions, malignancy, live vaccines, surgery, and mental illness in the protocol

“21. History of any immune-mediated or inflammatory medical condition for which patient requires current systemic (oral, SC, IM or IV) corticosteroids” (opens the source at this quote in a new tab)

“23. Known current malignancy or current evaluation for a potential malignancy or history of malignancy within the past 5 years prior to screening, except for adequately treated basal cell skin carcinoma, carcinoma in situ of the cervix and breast ductal carcinoma in situ” (opens the source at this quote in a new tab)

“24. Live vaccines (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, and bacillus Calmette-Guérin) within 4 weeks of Study Day 1” (opens the source at this quote in a new tab)

“25. Patient has a known hypersensitivity to any component of the study drug” (opens the source at this quote in a new tab)

“26. Patient has planned surgery during the study period” (opens the source at this quote in a new tab)

“27. Any acute or chronic illness/condition or evidence of an unstable clinical condition that in the investigator’s judgement will substantially increase the risk to the patient if he or she participates in the study” (opens the source at this quote in a new tab)

“28. History of mental illness within the last 5 years, unless the patient fulfills one of the following conditions:” (opens the source at this quote in a new tab)

“Receiving a fixed regimen of psychiatric medications for at least 6 months before screening, displays no sign of acute mental illness and, in the opinion of the investigator, the patient is able and safe to participate in the study” (opens the source at this quote in a new tab)

“Has not required or been prescribed any psychiatric medication (including but not limited to antidepressants or anxiolytics) within 12 months before screening and, in the opinion of the investigator, the patient is able and safe to participate in the study” (opens the source at this quote in a new tab)

“29. Patient who, for any reason, is deemed by the investigator to be inappropriate for this study or is unable to comply with the study protocol” (opens the source at this quote in a new tab)

Treatment
Arms and tablet regimens in the ClinicalTrials.gov results
Study outcomes
Rationale for using PASI 75 response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants per arm in the intent-to-treat, modified intent-to-treat, and safety analysis sets of the published article
Analysis set (table)PlaceboESK-001 10 mg QDESK-001 20 mg QDESK-001 20 mg BIDESK-001 40 mg QDESK-001 40 mg BID
Intent-to-treat (Table I)“(N = 38)”“(N = 36)”“(N = 36)”“(N = 40)”“(N = 39)”“(N = 39)”
Modified intent-to-treat (Table II)“(N = 38)”“(N = 36)”“(N = 36)”“(N = 39)”“(N = 39)”“(N = 39)”
Safety (Table III)“(N = 38)”“(N = 36)”“(N = 36)”“(N = 39)”“(N = 39)”“(N = 39)”
Analysis set (table)Pooled ESK-001 column header
Intent-to-treat (Table I)“ESK-001 pooled (N = 190)”
Safety (Table III)“ESK-001 pooled (N = 189)”
Description of analysis sets
Analysis populations, stratification factors, multiplicity, and treatment-emergent period in the statistical analysis plan

“Modified Intent-to-Treat (mITT) Population: All randomized subjects who received at least one dose of study drug, with analyses conducted according to the assigned treatment. This will be the analysis population used for the primary efficacy analysis at Week 12.” (opens the source at this quote in a new tab)

“Intent-to-treat (ITT) Population: All randomized subjects, regardless of whether they receive study drug, with analyses conducted according to the assigned treatment.” (opens the source at this quote in a new tab)

“Per-protocol (PP) Population: All subjects in the ITT population who have received at least one dose of study drug as assigned, have both baseline and at least one post-baseline PASI score, and have no important protocol deviations (IPD) which may affect key primary and secondary efficacy endpoints in the treatment period.” (opens the source at this quote in a new tab)

“Safety Analysis Population: All randomized subjects who receive at least one dose of study drug with analyses conducted by actual treatment received.” (opens the source at this quote in a new tab)

“PK Analysis Population: All randomized subjects who receive at least 1 dose of ESK-001 and have at least one non-missing PK concentration with analysis conducted by actual treatment received.” (opens the source at this quote in a new tab)

“Prior use of biologics or JAK inhibitors (yes/no)” (opens the source at this quote in a new tab)

“Geographic region (North America /rest of world (ROW))” (opens the source at this quote in a new tab)

“No adjustments for multiplicity control will be performed in this study.” (opens the source at this quote in a new tab)

“The treatment emergent period is defined as first dose through the end of study for subjects who complete the full treatment period of 12 weeks.” (opens the source at this quote in a new tab)

“If a subject discontinues study drug early, then the treatment emergent period will be first dose through four weeks after last dose.” (opens the source at this quote in a new tab)

“Since the EQ-5D-5L value sets used to calculate the index score are country-specific and there currently are none available for Czech Republic where some subjects are enrolled in this study, the value set for Poland will be used instead as the closest Eastern European country with available scoring instrument.” (opens the source at this quote in a new tab)

Analysis population for each outcome measure in the ClinicalTrials.gov results
Results
Participant disposition
Participant flow by arm with reasons for not completing in the ClinicalTrials.gov results
Participant flow, overall studyPlaceboESK-001 10 mg QDESK-001 20 mg QDESK-001 20 mg BIDESK-001 40 mg QDESK-001 40 mg BID
Started“38”“36”“36”“40”“39”“39”
Completed“33”“36”“30”“37”“33”“35”
Not completed“5”“0”“6”“3”“6”“4”
Reason: adverse event“0”“0”“2”“0”“1”“1”
Reason: discontinued prior to dosing due to the blood sample logistics“0”“0”“0”“1”“0”“0”
Reason: lost to follow-up“0”“0”“2”“1”“1”“0”
Reason: protocol violation“0”“0”“0”“0”“2”“0”
Reason: subject can't continue with week 16 visit“0”“0”“1”“0”“0”“0”
Reason: terminated from the study due to sponsor requirements“0”“0”“0”“1”“0”“0”
Reason: withdrawal by subject“5”“0”“1”“0”“2”“3”
Baseline characteristics
Demographic and baseline disease characteristics by arm in the intent-to-treat set
CharacteristicPlacebo, N = 38ESK-001 10 mg QD, N = 36ESK-001 20 mg QD, N = 36ESK-001 20 mg BID, N = 40ESK-001 40 mg QD, N = 39ESK-001 40 mg BID, N = 39ESK-001 pooled, N = 190
Mean age, years (SD)“49 (11.7)”“49 (12.7)”“44 (12.0)”“48 (12.5)”“50 (10.4)”“48 (14.2)”“48 (12.4)”
Male, n (%)“31 (82)”“24 (67)”“24 (67)”“23 (58)”“26 (67)”“26 (67)”“123 (65)”
Female, n (%)“7 (18)”“12 (33)”“12 (33)”“17 (43)”“13 (33)”“13 (33)”“67 (35)”
Race, American Indian or Alaska Native, n (%)“0 (0)”“0 (0)”“1 (3)”“0 (0)”“1 (3)”“0 (0)”“2 (1)”
Race, Asian, n (%)“4 (11)”“1 (3)”“2 (6)”“2 (5)”“2 (5)”“2 (5)”“9 (5)”
Race, Black or African American, n (%)“3 (8)”“4 (11)”“0 (0)”“1 (3)”“1 (3)”“1 (3)”“7 (4)”
Race, Native Hawaiian or Other Pacific Islander, n (%)“0 (0)”“1 (3)”“0 (0)”“2 (5)”“0 (0)”“0 (0)”“3 (2)”
Race, White, n (%)“27 (71)”“30 (83)”“31 (86)”“34 (85)”“33 (85)”“33 (85)”“161 (85)”
Race, other, n (%)“4 (11)”“0 (0)”“2 (6)”“1 (3)”“2 (5)”“1 (3)”“6 (3)”
Race, not reported, n (%)“0 (0)”“0 (0)”“0 (0)”“0 (0)”“0 (0)”“2 (5)”“2 (1)”
Ethnicity, Hispanic or Latino, n (%)“13 (34)”“7 (19)”“14 (39)”“7 (18)”“13 (33)”“11 (28)”“52 (27)”
Ethnicity, not Hispanic or Latino, n (%)“24 (63)”“29 (81)”“21 (58)”“33 (83)”“26 (67)”“28 (72)”“137 (72)”
Ethnicity, not reported, n (%)“1 (3)”“0 (0)”“1 (3)”“0 (0)”“0 (0)”“0 (0)”“1 (1)”
Mean weight, kg (SD)“94 (21.4)”“92 (21.3)”“103 (39.1)”“95 (24.7)”“88 (19.1)”“91 (20.9)”“94 (26.1)”
Mean BMI, kg/m2 (SD)“32 (6.8)”“31 (5.9)”“35 (12.1)”“32 (7.4)”“30 (6.4)”“32 (7.1)”“32 (8.1)”
Mean duration of psoriasis, years (SD)“20 (11.6)”“19 (13.4)”“17 (8.3)”“22 (12.2)”“17 (12.4)”“22 (15.5)”“19 (12.7)”
Prior treatment with biologics or JAK inhibitors, n (%)“13 (34)”“13 (36)”“14 (39)”“16 (40)”“13 (33)”“13 (33)”“69 (36)”
Mean PASI score (SD)“18 (4.5)”“17 (3.9)”“19 (6.6)”“18 (6.5)”“17 (6.5)”“17 (4.9)”“18 (5.8)”
sPGA score 3 (moderate), n (%)“22 (58)”“24 (67)”“17 (47)”“23 (58)”“25 (64)”“23 (59)”“112 (59)”
sPGA score 4 (marked), n (%)“15 (40)”“9 (25)”“17 (47)”“16 (40)”“14 (36)”“16 (41)”“72 (38)”
sPGA score 5 (severe), n (%)“1 (3)”“3 (8)”“2 (6)”“1 (3)”“0 (0)”“0 (0)”“6 (3)”
Mean BSA, % (SD)“23 (12.1)”“21 (12.2)”“20 (12.6)”“21 (15.0)”“20 (12.9)”“22 (15.1)”“21 (13.5)”
Mean DLQI score (SD)“10 (7.2)”“10 (5.4)”“9 (7.6)”“10 (7.2)”“10 (6.4)”“11 (6.8)”“10 (6.7)”
Age categories by arm in the ClinicalTrials.gov results
Age category, participantsPlacebo, n = 38ESK-001 10 mg QD, n = 36ESK-001 20 mg QD, n = 36ESK-001 20 mg BID, n = 40ESK-001 40 mg QD, n = 39ESK-001 40 mg BID, n = 39Total, n = 228
18 years or younger“0”“0”“0”“0”“0”“0”“0”
Between 18 and 65 years“35”“33”“33”“35”“37”“33”“206”
65 years or older“3”“3”“3”“5”“2”“6”“22”
Efficacy results
PASI 75, PASI 90, PASI 100, sPGA 0/1, sPGA 0, and BSA results at week 12 by dose in the modified intent-to-treat set
Week 12 end pointPlacebo, N = 38ESK-001 10 mg QD, N = 36ESK-001 20 mg QD, N = 36ESK-001 20 mg BID, N = 39ESK-001 40 mg QD, N = 39ESK-001 40 mg BID, N = 39
PASI-75, n (%)“0 (0)”“7 (19)”“12 (33)”“22 (56)”“22 (56)”“25 (64)”
PASI-75, P value vs placebo“-”“0.0025”“0.0001”“<0.0001”“<0.0001”“<0.0001”
PASI-75, difference vs placebo, % (95% CI)“-”“19 (−3, 41)”“33 (11, 54)”“56 (37, 73)”“56 (37, 73)”“64 (46, 79)”
PASI-90, n (%)“0 (0)”“0 (0)”“4 (11)”“10 (26)”“10 (26)”“15 (39)”
PASI-90, P value vs placebo“-”“-”“.0322”“.0007”“.0005”“<.0001”
PASI-90, difference vs placebo, % (95% CI)“-”“-”“11 (−12,34)”“26 (4, 46)”“26 (4, 46)”“39 (17, 58)”
PASI-100, n (%)“0 (0)”“0 (0)”“0 (0)”“4 (10)”“3 (8)”“6 (15)”
PASI-100, P value vs placebo“-”“-”“-”“.0396”“.0712”“.0127”
PASI-100, difference vs placebo, % (95% CI)“-”“-”“-”“10 (−12, 32)”“8 (−15, 30)”“15 (−7, 37)”
sPGA-0/1, n (%)“3 (8)”“6 (17)”“14 (39)”“19 (49)”“21 (54)”“23 (59)”
sPGA-0/1, P value vs placebo“-”“.1965”“.0012”“<.0001”“<.0001”“<.0001”
sPGA-0/1, difference vs placebo, % (95% CI)“-”“9 (−14, 32)”“31 (8, 51)”“41 (20, 60)”“46 (26, 65)”“51 (31, 69)”
sPGA-0, n (%)“0 (0)”“0 (0)”“0 (0)”“4 (10)”“4 (10)”“9 (23)”
sPGA-0, P value vs placebo“-”“-”“-”“.0396”“.0333”“.0017”
sPGA-0, difference vs placebo, % (95% CI)“-”“-”“-”“10 (−12, 32)”“10 (−12,32)”“23 (1, 44)”
Mean BSA change from baseline (SD)“−3 (6.8)”“−7 (7.8)”“−7 (8.1)”“−14 (12.9)”“−15 (14.2)”“−14 (12.1)”
Primary end point, dose-dependent response, and key secondary end points in the published article

“ESK-001 demonstrated both clinically meaningful and statistically significant dose-dependent improvements in psoriasis skin severity and quality of life” (opens the source at this quote in a new tab)

“A dose-dependent effect was observed across all end points, with maximal ESK-001 efficacy observed in the highest dose arm (40 mg BID).” (opens the source at this quote in a new tab)

“More patients achieved PASI-75 in each of the ESK-001 dose arms compared with placebo: 64% in the 40 mg BID dose arm vs 0% in the placebo group (P < .0001) at week 12, meeting the primary end point.” (opens the source at this quote in a new tab)

“Likewise, all key secondary end points were met in the 20 mg BID, 40 mg QD, and 40 mg BID dose arms.” (opens the source at this quote in a new tab)

“In patients receiving ESK-001 40 mg BID, 39% (P < .0001) and 15% (P = .0127) achieved PASI-90 and PASI-100, respectively (placebo, 0%).” (opens the source at this quote in a new tab)

“Furthermore, 59% (P < .0001) and 23% (P = .0017) achieved sPGA-0/1 and sPGA-0, respectively (placebo, 8% and 0%, respectively).” (opens the source at this quote in a new tab)

“Clinical responses to ESK-001 were robust and increased over time in all ESK-001 dose arms.” (opens the source at this quote in a new tab)

“In the 3 highest dose groups, clinically meaningful improvements in the primary and all secondary end points were achieved, including PASI, sPGA, DLQI, pruritus, and % body surface area involvement (P < .001).” (opens the source at this quote in a new tab)

PASI 75 response rates with 95% confidence intervals in the ClinicalTrials.gov results
Week 12 outcomePlacebo, n = 38ESK-001 10 mg QD, n = 36ESK-001 20 mg QD, n = 36ESK-001 20 mg BID, n = 39ESK-001 40 mg QD, n = 39ESK-001 40 mg BID, n = 39
PASI-75, percentage (95% CI)“0 (0.0 to 9.3)”“19.4 (8.2 to 36.0)”“33.3 (18.6 to 51.0)”“56.4 (36.6 to 72.2)”“56.4 (39.6 to 72.2)”“64.1 (47.2 to 78.8)”
Health-related quality of life and patient-reported outcomes
DLQI 0/1, DLQI 4-point decrease, and pruritus NRS results at week 12 by dose in the modified intent-to-treat set
Week 12 patient-reported outcomePlacebo, N = 38ESK-001 10 mg QD, N = 36ESK-001 20 mg QD, N = 36ESK-001 20 mg BID, N = 39ESK-001 40 mg QD, N = 39ESK-001 40 mg BID, N = 39
DLQI-0/1, n (%)“7 (18)”“10 (28)”“12 (33)”“20 (51)”“19 (48)”“25 (64)”
DLQI-0/1, P value vs placebo“-”“.2807”“.1159”“.0016”“.0045”“<.0001”
DLQI-0/1, difference vs placebo, % (95% CI)“-”“9 (−10, 29)”“15 (−5, 35)”“33 (13, 53)”“30 (10, 50)”“46 (26, 65)”
DLQI 4-point decrease, n (%)“7 (19)”“18 (51)”“18 (51)”“25 (64)”“26 (70)”“24 (65)”
DLQI 4-point decrease, P value vs placebo“-”“.0032”“.0032”“.0001”“<.0001”“<.0001”
DLQI 4-point decrease, difference vs placebo, % (95% CI)“-”“33 (12, 53)”“33 (12, 53)”“45 (26, 65)”“51 (32, 71)”“46 (26, 66)”
Mean change from baseline in average pruritus NRS (SD)“−1 (3)”“−2 (3)”“−3 (3)”“−4 (3)”“−4 (3)”“−5 (3)”
Mean change from baseline in worst pruritus NRS (SD)“−1 (3)”“−3 (3)”“−3 (4)”“−4 (3)”“−5 (3)”“−5 (3)”
Average pruritus NRS score <4, n (%)“11 (29)”“17 (47)”“21 (58)”“27 (69)”“27 (69)”“28 (72)”
Worst pruritus NRS score <4, n (%)“10 (26)”“17 (47)”“18 (50)”“26 (67)”“27 (69)”“29 (74)”
Median change in average and worst pruritus NRS at week 12 by dose in the congress poster
Week 12 pruritus NRS change from baseline, median (IQR)Placebo, N = 38ESK-001 10 mg QD, N = 36ESK-001 20 mg QD, N = 36ESK-001 20 mg BID, N = 39ESK-001 40 mg QD, N = 39ESK-001 40 mg BID, N = 39
Average pruritus NRS“0.0 (-3.0, 1.0)”“-2.0 (-3.0, 0.0)”“-2.5 (-6.0, 0.0)”“-3.0 (-5.0, -2.0)”“-5.0 (-6.0, -3.0)”“-4.0 (-8.0, -3.0)”
Worst pruritus NRS“-0.5 (-2.0, 1.0)”“-2.0 (-4.0, -1.0)”“-2.5 (-5.0, 1.0)”“-4.0 (-6.0, -1.0)”“-5.0 (-7.0, -3.0)”“-5.0 (-7.0, -3.0)”
EQ-5D results

No evidence found.

Safety results
Treatment-emergent adverse events by dose in the safety analysis set
Outcome, n (%)Placebo, N = 38ESK-001 10 mg QD, N = 36ESK-001 20 mg QD, N = 36ESK-001 20 mg BID, N = 39ESK-001 40 mg QD, N = 39ESK-001 40 mg BID, N = 39ESK-001 pooled, N = 189
TEAEs“15 (39.5)”“19 (52.8)”“14 (38.9)”“18 (46.2)”“19 (48.7)”“25 (64.1)”“95 (50.3)”
TEAEs leading to treatment discontinuation“0 (0.0)”“0 (0.0)”“2 (5.6)”“0 (0.0)”“2 (5.1)”“1 (2.6)”“5 (2.6)”
TEAEs grade 3 or higher“0 (0.0)”“3 (8.3)”“1 (2.8)”“3 (7.7)”“3 (7.7)”“0 (0.0)”“10 (5.3)”
TEAEs related to study drug“5 (13.2)”“3 (8.3)”“3 (8.3)”“5 (12.8)”“7 (17.9)”“9 (23.1)”“27 (14.3)”
Headache“2 (5.3)”“0 (0.0)”“2 (5.6)”“3 (7.7)”“4 (10.3)”“3 (7.7)”“12 (6.3)”
Upper respiratory tract infection“0 (0.0)”“2 (5.6)”“2 (5.6)”“1 (2.6)”“2 (5.1)”“3 (7.7)”“10 (5.3)”
Nasopharyngitis“3 (7.9)”“2 (5.6)”“0 (0.0)”“1 (2.6)”“1 (2.6)”“3 (7.7)”“7 (3.7)”
SAEs“0 (0.0)”“1 (2.8)”“0 (0.0)”“3 (7.7)”“1 (2.6)”“0 (0.0)”“5 (2.6)”
Deaths“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”
Overall tolerability, common adverse events, and absence of tuberculosis, herpes zoster, opportunistic infections, and oral ulcers in the published article

“ESK-001 was generally safe and well-tolerated in adult patients with moderate-to-severe psoriasis following 12 weeks of treatment and 4 weeks off treatment, with no dose-limiting safety findings and a study drug discontinuation rate of 2.6% due to AEs” (opens the source at this quote in a new tab)

“There were no deaths in this study.” (opens the source at this quote in a new tab)

“Overall, the most common AEs (occurring in >5% of patients in any treatment group) were headache (6.3%), upper respiratory tract infections (5.3%), and nasopharyngitis (3.7%).” (opens the source at this quote in a new tab)

“Rates of acne and folliculitis were 2.1% and 1.6%, respectively, with no dose dependency (data on file).” (opens the source at this quote in a new tab)

“AEs were reported in 40% and in 39% to 64% of the patients in the placebo group and active-drug groups, respectively, with the highest percentage in the 40 mg BID dose group.” (opens the source at this quote in a new tab)

“TEAEs related to study drug occurred in 23% of subjects receiving 40 mg BID dose, 14.3% of subjects in pooled ESK-001 groups, and 13.2% of placebo subjects.” (opens the source at this quote in a new tab)

“Across all groups, the majority of TEAEs were mild or moderate and resolved.” (opens the source at this quote in a new tab)

“There were no cases of tuberculosis, herpes zoster, opportunistic infections, or oral ulcers.” (opens the source at this quote in a new tab)

“In addition, laboratory and electrocardiogram findings showed no meaningful changes during 12 weeks of ESK-001 treatment” (opens the source at this quote in a new tab)

Serious adverse events by arm, with the gastrointestinal event in the 20 mg twice-daily arm reported as enterocolitis, enteritis, or colitis and enteritis
Other adverse events reported in at least 5% of participants in any arm in the ClinicalTrials.gov results
Other (not serious) adverse event, affected / at risk (%)PlaceboESK-001 10 mg QDESK-001 20 mg QDESK-001 20 mg BIDESK-001 40 mg QDESK-001 40 mg BID
Total“9/38 (23.68%)”“8/36 (22.22%)”“4/36 (11.11%)”“18/39 (46.15%)”“11/39 (28.21%)”“18/39 (46.15%)”
Diarrhea“0/38 (0.00%)”“1/36 (2.78%)”“0/36 (0.00%)”“2/39 (5.13%)”“1/39 (2.56%)”“0/39 (0.00%)”
Dyspepsia“0/38 (0.00%)”“0/36 (0.00%)”“0/36 (0.00%)”“2/39 (5.13%)”“0/39 (0.00%)”“0/39 (0.00%)”
Nausea“1/38 (2.63%)”“0/36 (0.00%)”“0/36 (0.00%)”“2/39 (5.13%)”“0/39 (0.00%)”“0/39 (0.00%)”
Pyrexia“0/38 (0.00%)”“0/36 (0.00%)”“0/36 (0.00%)”“1/39 (2.56%)”“0/39 (0.00%)”“2/39 (5.13%)”
Upper respiratory tract infection“0/38 (0.00%)”“2/36 (5.56%)”“2/36 (5.56%)”“1/39 (2.56%)”“2/39 (5.13%)”“3/39 (7.69%)”
Nasopharyngitis“3/38 (7.89%)”“2/36 (5.56%)”“0/36 (0.00%)”“1/39 (2.56%)”“1/39 (2.56%)”“3/39 (7.69%)”
COVID-19“3/38 (7.89%)”“0/36 (0.00%)”“0/36 (0.00%)”“1/39 (2.56%)”“0/39 (0.00%)”“1/39 (2.56%)”
Diabetes mellitus“0/38 (0.00%)”“2/36 (5.56%)”“0/36 (0.00%)”“1/39 (2.56%)”“0/39 (0.00%)”“0/39 (0.00%)”
Headache“2/38 (5.26%)”“0/36 (0.00%)”“2/36 (5.56%)”“3/39 (7.69%)”“4/39 (10.26%)”“3/39 (7.69%)”
Dizziness“0/38 (0.00%)”“0/36 (0.00%)”“0/36 (0.00%)”“2/39 (5.13%)”“1/39 (2.56%)”“0/39 (0.00%)”
Cough“0/38 (0.00%)”“0/36 (0.00%)”“0/36 (0.00%)”“2/39 (5.13%)”“0/39 (0.00%)”“2/39 (5.13%)”
Acne“0/38 (0.00%)”“0/36 (0.00%)”“0/36 (0.00%)”“0/39 (0.00%)”“2/39 (5.13%)”“2/39 (5.13%)”
Dermatitis acneiform“0/38 (0.00%)”“1/36 (2.78%)”“0/36 (0.00%)”“0/39 (0.00%)”“0/39 (0.00%)”“2/39 (5.13%)”
Absence of MACE, serious infections, treatment-related thromboses, and laboratory or ECG trends in the congress presentation
Study limitations
Summary
  • The authors cite the small sample size per treatment group and the 16-week study duration, and the exclusion of participants who were previously nonresponders to IL-17, IL-12, or IL-23 targeted therapies. The protocol also excluded participants with lack of response to 2 or more biologic therapies.
  • The primary endpoint was assessed at week 12, when, according to the authors, response trajectories suggested maximal efficacy had not yet been achieved.
  • The statistical analysis plan states that no adjustments for multiplicity were performed.
  • The analysis population for efficacy differs by source: the protocol planned intent-to-treat analyses, the article used the modified intent-to-treat population, and the ClinicalTrials.gov results describe the PASI 75 population as all randomized and treated participants. The 20 mg BID arm has 40 participants in the intent-to-treat set and 39 in the modified intent-to-treat and safety sets.
  • The number of sites is 30 in the article, 53 in the ClinicalTrials.gov record, and approximately 65 planned in the protocol.
  • The serious gastrointestinal event in the 20 mg BID arm is reported as enterocolitis (article table footnote), enteritis of unknown etiology (article text), colitis and enteritis as separate terms (ClinicalTrials.gov results), and colitis and enteritis in one subject (congress presentation).
  • The article reports 5 participants (2.6%) discontinuing envudeucitinib due to an AE; the ClinicalTrials.gov participant flow lists an adverse event as the reason for not completing the study for 2 (20 mg QD), 1 (40 mg QD), and 1 (40 mg BID) participants.
  • The DLQI decrease of at least 4 points with 40 mg BID is 65% in the article and 62% in the patient-reported outcomes poster.
  • Acne and folliculitis rates are cited as data on file, skin biopsies were optional and collected from approximately 5 to 12 participants per dose group, and the report holds no EQ-5D results.

STRIDE open-label extension

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent and serious adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Analysis sets by arm, ITT population
Analysis setOriginal 40 mg QD (N = 82)Original 40 mg BID (N = 83)40 mg QD to 40 mg BID (N = 65)Overall 40 mg BID (N = 148)Overall (N = 165)
ITT population“82”“83”“65”“148”“165”
mITT population“82 (100.0)”“82 (98.8)”“65 (100.0)”“147 (99.3)”“164 (99.4)”
Safety analysis set“82 (100.0)”“82 (98.8)”“65 (100.0)”“147 (99.3)”“164 (99.4)”
PK analysis set“82 (100.0)”“82 (98.8)”“65 (100.0)”“147 (99.3)”“164 (99.4)”
Results
Participant disposition
Disposition by arm, ITT population
DispositionOriginal 40 mg QD (N = 82)Original 40 mg BID (N = 83)40 mg QD to 40 mg BID (N = 65)Overall 40 mg BID (N = 148)Overall (N = 165)
Patients ongoing in study, n (%)“0 (0)”“66 (79.5)”“60 (92.3)”“126 (85.1)”“126 (76.4)”
Patients who switched to 40 mg BID, n (%)“65 (79.3)”“-”“-”“-”“65 (39.4)”
Discontinued: withdrawal by subject“6 (7.3)”“3 (3.6)”“4 (6.2)”“7 (4.7)”“13 (7.9)”
Discontinued: lost to follow-up“3 (3.7)”“6 (7.2)”“1 (1.5)”“7 (4.7)”“10 (6.1)”
Discontinued: inadequate response“6 (7.3)”“1 (1.2)”“0 (0)”“1 (0.7)”“7 (4.2)”
Discontinued: adverse event“1 (1.2)”“4 (4.8)”“0 (0)”“4 (2.7)”“5 (3.0)”
Discontinued: pregnancy“1 (1.2)”“0 (0)”“0 (0)”“0 (0)”“1 (0.6)”
Discontinued: protocol deviation“0 (0)”“1 (1.2)”“0 (0)”“1 (0.7)”“1 (0.6)”
Discontinued: death“0 (0)”“0 (0)”“0 (0)”“0 (0)”“0 (0)”
Baseline characteristics
Demographic and baseline characteristics by original dose assignment, ITT population
CharacteristicOriginal 40 mg QD (N = 82)Original 40 mg BID (N = 83)Overall (N = 165)
Age (y), mean (SD)“47.5 (12.7)”“50.8 (12.1)”“49.2 (12.4)”
Male, n (%)“56 (68.3)”“61 (73.5)”“117 (70.9)”
Female, n (%)“26 (31.7)”“22 (26.5)”“48 (29.1)”
Race: Asian, n (%)“7 (8.5)”“4 (4.8)”“11 (6.7)”
Race: Black or African American, n (%)“5 (6.1)”“1 (1.2)”“6 (3.6)”
Race: Native Hawaiian or Other Pacific Islander, n (%)“1 (1.2)”“2 (2.4)”“3 (1.8)”
Race: White, n (%)“63 (76.8)”“70 (84.3)”“133 (80.6)”
Race: Other, n (%)“6 (7.3)”“5 (6.0)”“11 (6.7)”
Ethnicity: Hispanic or Latino, n (%)“26 (31.7)”“25 (30.1)”“51 (30.9)”
Weight (kg), mean (SD)“98.1 (28.5)”“94.0 (23.2)”“96.0 (26.0)”
BMI (kg/m2), mean (SD)“33.1 (8.8)”“31.7 (7.4)”“32.4 (8.1)”
Duration of psoriasis (y), mean (SD)“17.2 (10.9)”“22.3 (14.3)”“19.8 (13.0)”
Prior treatment with biologics, n (%)“37 (45.1)”“42 (50.6)”“79 (47.9)”
Prior treatment with JAKi, n (%)“1 (1.2)”“3 (3.6)”“4 (2.4)”
PASI, mean (SD)“10.2 (7.2)”“6.8 (7.0)”“8.5 (7.2)”
sPGA score 0, n (%)“1 (1.2)”“5 (6.0)”“6 (3.6)”
sPGA score 1, n (%)“10 (12.2)”“26 (31.3)”“36 (21.8)”
sPGA score 2, n (%)“19 (23.2)”“19 (22.9)”“38 (23.0)”
sPGA score 3, n (%)“39 (47.6)”“23 (27.7)”“62 (37.6)”
sPGA score 4, n (%)“12 (14.6)”“7 (8.4)”“19 (11.5)”
BSA involvement (%), mean (SD)“12.9 (13.4)”“8.7 (11.1)”“10.8 (12.5)”
DLQI, mean (SD)“5.8 (5.8)”“4.5 (4.8)”“5.2 (5.3)”
Average pruritus NRS score, mean (SD)“4.6 (3.0)”“4.0 (3.1)”“4.3 (3.1)”
Efficacy results
Week 28 and week 52 skin responses by original and overall 40 mg twice-daily groups, mITT population, mNRI
EndpointWeek 28, original 40 mg QD (N = 80)Week 52, original 40 mg BID (N = 80)Week 52, overall 40 mg BID (N = 144)
PASI-75, n (%)“54 (67.5)”“62 (77.5)”“112 (77.8)”
PASI-75, 95% CI“56.1, 77.6”“66.8, 86.1”“70.1, 84.3”
PASI-90, n (%)“36 (45.0)”“49 (61.3)”“90 (62.5)”
PASI-90, 95% CI“33.8, 56.5”“49.7, 71.9”“54.1, 70.4”
PASI-100, n (%)“15 (18.8)”“31 (38.8)”“47 (32.6)”
PASI-100, 95% CI“10.9, 29.0”“28.1, 50.3”“25.1, 40.9”
sPGA-0/1, n (%)“41 (51.3)”“49 (61.3)”“86 (59.7)”
sPGA-0/1, 95% CI“39.8, 62.6”“49.7, 71.9”“51.2, 67.8”
sPGA-0, n (%)“15 (18.8)”“31 (38.8)”“47 (32.6)”
sPGA-0, 95% CI“10.9, 29.0”“28.1, 50.3”“25.1, 40.9”
Improvement in PASI response category from STRIDE week 12 to extension week 52, 40 mg twice daily, mITT population
Responder status at week 12 of STRIDENImprovement to PASI-75, n (%)Improvement to PASI-90, n (%)Improvement to PASI-100, n (%)Any improvement, n (%)
Below PASI-75“38”“7 (18.4)”“8 (21.1)”“12 (31.6)”“27 (71.1)”
PASI-75 and below PASI-90“24”“----”“4 (16.7)”“10 (41.7)”“14 (58.3)”
PASI-90 and below PASI-100“11”“----”“----”“4 (36.4)”“4 (36.4)”
Total“73”“----”“----”“----”“45 (61.6)”
Health-related quality of life and patient-reported outcomes
Week 28 and week 52 patient-reported outcomes by original and overall 40 mg twice-daily groups, mITT population, mNRI
EndpointWeek 28, original 40 mg QD (N = 80)Week 52, original 40 mg BID (N = 80)Week 52, overall 40 mg BID (N = 144)
DLQI 0/1, n (%)“41 (51.3)”“49 (61.3)”“87 (60.4)”
DLQI 0/1, 95% CI“39.8, 62.6”“49.7, 71.9”“51.9, 68.5”
DLQI 4-point decrease, n (%)“49 (61.3)”“55 (68.8)”“103 (71.5)”
DLQI 4-point decrease, 95% CI“49.7, 71.9”“57.4, 78.7”“63.4, 78.7”
Average pruritus NRS score below 4, n (%)“54 (67.5)”“65 (81.3)”“115 (79.9)”
Average pruritus NRS score below 4, 95% CI“56.1, 77.6”“71.0, 89.1”“72.4, 86.1”
Worst pruritus NRS score below 4, n (%)“51 (63.8)”“63 (78.8)”“112 (77.8)”
Worst pruritus NRS score below 4, 95% CI“52.2, 74.2”“68.2, 87.1”“70.1, 84.3”
Improvement in worst pruritus NRS score of at least 4, post-hoc, n (%)“44 (55.0)”“47 (58.8)”“89 (61.8)”
Improvement in worst pruritus NRS score of at least 4, post-hoc, 95% CI“43.5, 66.2”“47.2, 69.6”“53.3, 69.8”
Safety results
Adverse events with exposure-adjusted incidence rates through week 52, safety analysis population
Event, n (%) [EAIR]Original 40 mg QD (N = 82)Overall 40 mg BID (N = 147)Overall (N = 164)
Patients with at least 1 TEAE“50 (61.0) [122.76]”“73 (49.7) [102.33]”“108 (65.9) [108.18]”
Patients with TEAE leading to study drug discontinuation“1 (1.2) [1.55]”“5 (3.4) [4.19]”“6 (3.7) [3.26]”
Patients with TEAE grade 3 or higher“3 (3.7) [4.66]”“6 (4.1) [5.12]”“8 (4.9) [4.42]”
Upper respiratory tract infection“3 (3.7) [4.71]”“13 (8.8) [11.66]”“16 (9.8) [9.20]”
Nasopharyngitis“10 (12.2) [16.88]”“6 (4.1) [5.15]”“14 (8.5) [8.09]”
COVID-19“3 (3.7) [4.74]”“8 (5.4) [6.88]”“11 (6.7) [6.17]”
Headache“5 (6.1) [8.28]”“5 (3.4) [4.28]”“10 (6.1) [5.71]”
Patients with at least 1 treatment-emergent SAE“2 (2.4) [3.10]”“4 (2.7) [3.39]”“6 (3.7) [3.29]”
Patients with SAEs related to study drug“2 (2.4) [3.10]”“2 (1.4) [1.67]”“4 (2.4) [2.17]”
Patients with TEAE leading to death“0 (0) [-]”“0 (0) [-]”“0 (0) [-]”
Study limitations
Summary
  • The authors state that this was an open-label study with limited sample size and no placebo or active comparator.
  • No formal power calculation was performed; the sample consisted of STRIDE completers who qualified and chose to enroll. The extension was not initiated in the Czech Republic, which made 25 STRIDE completers ineligible, and the study was conducted at North American sites only.
  • Dose assignment followed the STRIDE arm for participants from the 10 mg QD and 20 mg QD arms (40 mg QD) and the 20 mg BID and 40 mg BID arms (40 mg BID); participants from the placebo and 40 mg QD arms were allocated to either dose. The ClinicalTrials.gov record lists the allocation as randomized.
  • A protocol amendment on 2 January 2024 moved all participants to 40 mg BID between weeks 40 and 64, so the overall 40 mg BID group (N = 148, intent-to-treat) includes 65 participants who switched from 40 mg QD.
  • Efficacy baseline was STRIDE Day 1, and participants entered the extension with a mean PASI of 8.5. Responder analyses used modified nonresponder imputation, carrying the last observation forward for discontinuations other than for AEs or inadequate response.
  • Week 52 PASI 100 with 40 mg BID is 39% in the article text, 31 of 80 (38.8%) in the original 40 mg BID group, and 47 of 144 (32.6%) in the overall 40 mg BID group. Itch control in the original 40 mg BID group is reported as “NRS≤4, 81.3%” in a press release and as average pruritus NRS below 4 in 65 participants (81.3%) in the article table.
  • Data cutoffs differ: the supplement includes data from 18 November 2024, and a congress poster by Blauvelt et al. displays safety data from the 06 SEP 2024 data cut. The treat-to-target analyses and the analysis of an improvement of at least 4 points in worst pruritus NRS are post hoc.
  • The study is ongoing; 126 participants (76.4%) were continuing treatment at the 52-week data cut-off, and study completion is estimated for 2027-12-31.

ACTRN12621000011886

Objective
Location and study date
Registration, enrollment, and data collection dates in the ANZCTR record
FieldQuoted record
Date submitted“26/11/2020”
Date registered“11/01/2021”
Type of registration“Prospectively registered”
Recruitment status“Completed”
Date of first participant enrolment, anticipated“29/01/2021”
Date of first participant enrolment, actual“17/02/2021”
Date of last participant enrolment, anticipated“17/11/2021”
Date of last participant enrolment, actual“19/01/2022”
Date of last data collection, anticipated“30/11/2021”
Date of last data collection, actual“4/02/2022”
Date last updated“14/06/2022”
Recruitment state and principal investigator site in Adelaide, Australia, in the ANZCTR record
Results documents and data sharing in the ANZCTR record
FieldQuoted record
Will the study consider sharing individual participant data?“No”
Study design
Study type, allocation, control, and phase in the ANZCTR record
FieldQuoted record
Health condition(s) studied“Psoriasis”
Study type“Interventional”
Purpose of the study“Treatment”
Allocation to intervention“Randomised controlled trial”
Control group“Placebo”
Phase“Phase 1”
Secondary sponsor, funding, and ethics approval in the ANZCTR record
FieldQuoted record
Funding source category“Commercial sector/Industry”
Secondary sponsor name“Avance Clinical Pty Ltd”
Ethics committee name“Bellberry Human Research Ethics Committee”
Ethics approval date“10/12/2020”
Ethics approval number“2020-11-1116”
Eligibility criteria
Key exclusion criteria in the ANZCTR record
CriterionQuoted record
Significant disease“History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within the past 3 months determined by the PI to be clinically relevant.”
Current infection“Current infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medications.”
Malignancy“Any history of malignant disease in the last 10 years (excludes surgically resected skin squamous cell or basal cell carcinoma).”
Immunosuppression“Presence of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.”
Immunosuppressive or immunomodulating medications“Use of or plans to use systemic immunosuppressive (e.g., corticosteroids, methotrexate, azathioprine, cyclosporine) or immunomodulating medications (e.g., interferon) during the study or within 3 months prior to the first study drug administration.”
Skin findings“Presence or evidence of recent sunburn, scar tissue, tattoo (more than 25% of body area), open sore, or branding that, in the opinion of the Investigator, would interfere with interpretation of skin adverse reaction assessments.”
Liver function tests“Liver function test results elevated more than 1.5-fold above the upper limit of normal (ULN) for gamma glutamyl transferase [GGT], bilirubin (total, conjugated and unconjugated) or alkaline phosphatase (ALP) or elevated 2.0-fold above ULN for aspartate aminotransferase (AST) or alanine aminotransferase (ALT).”
Viral infection“Positive test results for active human immunodeficiency virus (HIV-1 and HIV-2), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at the screening visit.”
Tuberculosis“History of active, latent or inadequately treated tuberculosis infection.”
Conditions affecting drug disposition“Presence or having sequelae of gastrointestinal, liver (including Gilbert’s syndrome), kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.”
Renal function“Estimated creatinine clearance (CrCl) < 60 mL/min using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.”
Concomitant medication“Use of any systemically absorbed prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 10 days or 5 half-lives of the medication (whichever is longer) prior to the first study drug administration, except occasional use of paracetamol (up to a maximum of 4 doses per day of 500-mg paracetamol, and no more than 3g per week).”
Interferon hypersensitivity“Known hypersensitivity to interferon alfa or any component of the product (Part B only).”
Vaccination“Use of any vaccinations within 30 days prior to the first study drug administration.”
Other investigational trials“Participation in another investigational clinical trial within 60 days (or 5 half-lives, of the investigational agent) (whichever is longer) prior to the first study drug administration.”
Treatment
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Primary and secondary outcomes in the ANZCTR record
Statistical analysis description
Number of participants (Planned and analyzed)
Target and final sample size in the ANZCTR record
FieldQuoted record
Sample size, target“96”
Sample size, final“87”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Plasma pharmacokinetic parameters by single ascending dose and food effect cohort
Parameter5 mg fasted10 mg fasted17.5 mg fasted25 mg fasted50 mg fasted100 mg fastedFood effect cohort, 25 mg fastedFood effect cohort, 25 mg fed
Participants“5 mg Fasted (N = 6)”View highlighted excerpt for this quote“10 mg Fasted (N = 6)”View highlighted excerpt for this quote“17.5 mg Fasted (N = 4)”View highlighted excerpt for this quote“25 mg Fasted (N = 5)”View highlighted excerpt for this quote“50 mg Fasted (N = 5)”View highlighted excerpt for this quote“100 mg Fasted (N = 5)”View highlighted excerpt for this quote“FE cohort 25 mg Fasted (N = 6)”View highlighted excerpt for this quote“FE cohort 25 mg Fed (N = 6)”View highlighted excerpt for this quote
Cmax, ng/mL“38.6 (22)”View highlighted excerpt for this quote“93.0 (28)”View highlighted excerpt for this quote“217 (19)”View highlighted excerpt for this quote“253 (21)”View highlighted excerpt for this quote“603 (24)”View highlighted excerpt for this quote“949 (15)”View highlighted excerpt for this quote“272 (13)”View highlighted excerpt for this quote“131 (22)”View highlighted excerpt for this quote
Tmax, h“0.75 (0.75–2.00)”View highlighted excerpt for this quote“0.88 (0.75–4.00)”View highlighted excerpt for this quote“1.13 (0.75–2.00)”View highlighted excerpt for this quote“1.00 (1.00–1.50)”View highlighted excerpt for this quote“1.00 (0.50–1.50)”View highlighted excerpt for this quote“1.00 (0.75–6.00)”View highlighted excerpt for this quote“0.75 (0.50–1.00)”View highlighted excerpt for this quote“4.00 (4.00–6.00)”View highlighted excerpt for this quote
AUC0–t, h*ng/mL“326 (29)”View highlighted excerpt for this quote“794 (24)”View highlighted excerpt for this quote“1896 (5)”View highlighted excerpt for this quote“2110 (18)”View highlighted excerpt for this quote“4097 (24)”View highlighted excerpt for this quote“11,092 (14)”View highlighted excerpt for this quote“1829 (13)”View highlighted excerpt for this quote“1802 (20)”View highlighted excerpt for this quote
AUC0–inf, h*ng/mL“336 (28)”View highlighted excerpt for this quote“816 (26)”View highlighted excerpt for this quote“1925 (5)”View highlighted excerpt for this quote“2138 (18)”View highlighted excerpt for this quote“4137 (24)”View highlighted excerpt for this quote“11,286 (14)”View highlighted excerpt for this quote“1850 (14)”View highlighted excerpt for this quote“1833 (20)”View highlighted excerpt for this quote
AUC0–24h, h*ng/mL“283 (26)”View highlighted excerpt for this quote“675 (18)”View highlighted excerpt for this quote“1662 (4)”View highlighted excerpt for this quote“1873 (20)”View highlighted excerpt for this quote“3678 (21)”View highlighted excerpt for this quote“9379 (14)”View highlighted excerpt for this quote“1642 (13)”View highlighted excerpt for this quote“1550 (20)”View highlighted excerpt for this quote
t½, h“8.66 (22)”View highlighted excerpt for this quote“9.26 (18)”View highlighted excerpt for this quote“7.85 (19)”View highlighted excerpt for this quote“7.97 (11)”View highlighted excerpt for this quote“7.48 (10)”View highlighted excerpt for this quote“8.11 (13)”View highlighted excerpt for this quote“7.60 (17)”View highlighted excerpt for this quote“7.91 (14)”View highlighted excerpt for this quote
CL/F, L/h“14.9 (36)”View highlighted excerpt for this quote“12.3 (21)”View highlighted excerpt for this quote“9.1 (5)”View highlighted excerpt for this quote“11.7 (17)”View highlighted excerpt for this quote“12.1 (23)”View highlighted excerpt for this quote“8.9 (13)”View highlighted excerpt for this quote“13.5 (13)”View highlighted excerpt for this quote“13.6 (21)”View highlighted excerpt for this quote
Vz/F, L“186 (20)”View highlighted excerpt for this quote“164 (13)”View highlighted excerpt for this quote“103 (18)”View highlighted excerpt for this quote“134 (27)”View highlighted excerpt for this quote“130 (14)”View highlighted excerpt for this quote“104 (20)”View highlighted excerpt for this quote“148 (19)”View highlighted excerpt for this quote“156 (28)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events by single ascending dose cohort
Event5 mg fasted (N = 6)10 mg fasted (N = 6)17.5 mg fasted (N = 4)25 mg fasted (N = 6)50 mg fasted (N = 6)100 mg fasted (N = 5)Food effect cohort, 25 mg fasted (N = 7)Food effect cohort, 25 mg fed (N = 7)Total active (N = 41)Pooled placebo (N = 12)
Participant with at least 1 TEAE“3 (50.0) [7]”View highlighted excerpt for this quote“3 (50.0) [4]”View highlighted excerpt for this quote“3 (75.0) [8]”View highlighted excerpt for this quote“4 (66.6) [8]”View highlighted excerpt for this quote“6 (100.0) [18]”View highlighted excerpt for this quote“5 (100.0) [22]”View highlighted excerpt for this quote“4 (57.1) [14]”View highlighted excerpt for this quote“4 (57.1) [15]”View highlighted excerpt for this quote“32 (78.0) [96]”View highlighted excerpt for this quote“5 (41.6) [9]”View highlighted excerpt for this quote
Mild“3 (50.0) [6]”View highlighted excerpt for this quote“3 (50.0) [4]”View highlighted excerpt for this quote“3 (75.0) [8]”View highlighted excerpt for this quote“4 (66.6) [8]”View highlighted excerpt for this quote“6 (100.0) [18]”View highlighted excerpt for this quote“5 (100.0) [20]”View highlighted excerpt for this quote“4 (57.1) [13]”View highlighted excerpt for this quote“4 (57.1) [13]”View highlighted excerpt for this quote“32 (78.0) [90]”View highlighted excerpt for this quote“5 (41.6) [9]”View highlighted excerpt for this quote
Moderate“1 (16.6) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (40.0) [2]”View highlighted excerpt for this quote“1 (14.2) [1]”View highlighted excerpt for this quote“2 (28.5) [2]”View highlighted excerpt for this quote“6 (14.6) [6]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Severe“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAEs considered related to the study drug“1 (16.6) [2]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (75.0) [5]”View highlighted excerpt for this quote“4 (66.6) [6]”View highlighted excerpt for this quote“4 (66.6) [8]”View highlighted excerpt for this quote“5 (100.0) [20]”View highlighted excerpt for this quote“4 (57.1) [5]”View highlighted excerpt for this quote“4 (57.1) [9]”View highlighted excerpt for this quote“25 (60.9) [55]”View highlighted excerpt for this quote“2 (16.6) [3]”View highlighted excerpt for this quote
TEAEs leading to study drug discontinuation“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (14.2) [1]”View highlighted excerpt for this quote“1 (2.4) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Any serious TEAE“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Headache“0”View highlighted excerpt for this quote“2 (33.3) [2]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (33.3) [3]”View highlighted excerpt for this quote“5 (83.3) [5]”View highlighted excerpt for this quote“5 (100.0) [5]”View highlighted excerpt for this quote“3 (42.8) [3]”View highlighted excerpt for this quote“3 (42.8) [6]”View highlighted excerpt for this quote“20 (48.7) [24]”View highlighted excerpt for this quote“3 (25.0) [3]”View highlighted excerpt for this quote
Dizziness“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (25.0) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (20.0) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (28.5) [2]”View highlighted excerpt for this quote“4 (9.7) [4]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Fatigue“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (75.0) [4]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (20.0) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (9.7) [5]”View highlighted excerpt for this quote“1 (8.3) [1]”View highlighted excerpt for this quote
Nausea“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (16.6) [1]”View highlighted excerpt for this quote“2 (33.3) [2]”View highlighted excerpt for this quote“5 (100) [5]”View highlighted excerpt for this quote“1 (14.2) [1]”View highlighted excerpt for this quote“1 (14.2) [1]”View highlighted excerpt for this quote“10 (24.3) [10]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Catheter site bruise“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (16.6) [2]”View highlighted excerpt for this quote
Incidence, severity, relatedness, and discontinuations in the single ascending dose part

“In the SAD part, 37 (69.8%) participants experienced 105 TEAEs; 32 (78.0%) participants receiving ESK‐001 experienced 96 TEAEs and 5 (41.6%) participants receiving placebo experienced 9 TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Most TEAEs (94.3%) were mild in severity and a few moderate in severity (all following administration of ESK‐001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There were no dose‐related trends in the incidence and severity of TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Two participants in the FE cohort discontinued the study drug and study due to TEAEs indicative of a possible COVID‐19 infection, one after 1 dose (fed) in Period 1 due to upper respiratory tract infection, and one after 1 dose (fasted) in Period 1 due to sinus congestion, cough, and sneezing, all mild in severity and not related to study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most common TEAE (reported in ≥30% of the participants in any group) by preferred term was a headache.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the cohorts receiving ESK‐001, most TEAEs were considered related to the study drug by the investigator; 25 (61.0%) participants receiving ESK‐001 experienced 55 TEAEs considered related to the study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Two (16.6%) participants receiving placebo experienced 3 TEAEs considered related to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There were no apparent treatment or dose‐related trends in the clinical laboratory results and no TEAEs arising from abnormalities in clinical laboratory results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Study limitations
Summary
  • The authors note that the study provided short-term exposure data, so chronic effects such as cumulative toxicity were not captured.
  • The multiple ascending dose part is reported in supplementary figures and tables, and its biomarker results and the concentration-QTc results are reported as data not shown.
  • Participants were healthy adults dosed with a liquid formulation of ESK-001.
  • Because of the COVID-19 pandemic, the 17.5 mg and 100 mg cohorts could not be filled to the planned 8 participants (N = 4 and N = 5 in the pharmacokinetic table), and 2 food effect cohort participants withdrew with TEAEs indicative of a possible COVID-19 infection.
  • The article and the registry differ: the article reports 91 participants enrolled and a study conducted between January 21, 2021 and February 24, 2022; the ANZCTR record gives a final sample size of 87, a first enrolment on 17/02/2021, and a last data collection on 4/02/2022.
  • No formal sample size calculation was performed. Feces were collected but not analyzed, and urine was collected only for the 50 mg cohort of the single ascending dose part.
  • The ANZCTR record states that no documents have been uploaded by study researchers and answers No to whether the study will consider sharing individual participant data.

ESK-001-003

Objective
Location and study date
Recruitment and results status in the ClinicalTrials.gov record
FieldQuoted record
Overall status“Completed”
Results“No Results Posted”
Last update posted“2023-05-09”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using adverse event incidence as the primary endpoint
Primary and secondary outcome measures in the ClinicalTrials.gov record
RoleOutcome measureMeasure descriptionTime frame
Primary“Incidence of Adverse Events (AEs)”“Safety and tolerability”“Up to 14 days”
Primary“Incidence of Serious Adverse Events (SAEs)”“Safety and tolerability”“Up to 14 days”
Secondary“The area under plasma concentration-time curve from time zero extrapolated to last measurable concentration (AUCt) for ESK001 on Day 1 and Day 14”“Pharmacokinetics”“Up to 14 days”
Secondary“The area under the plasma concentration-curve over the dosing interval (AUC(0-τ)) for ESK001 on Day1 and Day 14”“Pharmacokinetics”“Up to 14 days”
Secondary“The observed maximum plasma concentration (Cmax) for ESK001 on Day 1 and Day 14.”“Pharmacokinetics”“Up to 14 days”
Secondary“The time to reach the observed maximum plasma concentration (tmax) for ESK001 on Day 1 and Day 14.”“Pharmacokinetics”“Up to 14 days”
Secondary“Apparent plasma elimination half-life (t½λz) for ESK001 on Day 1 and Day 14”“Pharmacokinetics”“Up to 14 days”
Secondary“Apparent clearance CL(Clearance)/F for ESK001 on Day 1”“Pharmacokinetics”“Up to 14 days”
Secondary“The accumulation ratio for AUC(0-τ) (RAC AUC(0-τ)) for ESK001 on Day 14”“Pharmacokinetics”“Up to 14 days”
Secondary“The accumulation ratio for Cmax (RAC Cmax) for ESK001 on Day 14.”“Pharmacokinetics”“Up to 14 days”
Secondary“Cytokine induction of pSTAT expression and downstream cytokine production as a measure of tyk2 pathway inhibition by ESK001”“Pharmacodynamics”“14 days after first dose”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Absorption, half-life, dose proportionality, steady state, and accumulation with the tablet

“ESK‐001 was rapidly absorbed into the systemic circulation with a median T max of 1.5–3.1 h on Day 1 following a single dose, and 1.1–2.2 h on Day 14 following multiple q.d. or Q12 doses (Figure 3b, Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mean t½ after the last dose on Day 14 ranged from 7.6 to 12.4 h across all q.d. or Q12 doses and no trend with dose or dose regimen was observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Similarly, no trend with dose was observed for geometric mean apparent steady‐state volume of distribution (Vss/F) and mean apparent total plasma clearance (CL/F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After multiple q.d. doses and after the first dose administration of Q12 doses, AUC from time zero to time tau (AUC0–tau) appeared to increase in a dose‐proportional manner (slope estimates [95% CI] were 0.934 [0.62;1.25] and 0.992 [0.49, 1.49], respectively), although 95% CIs were wide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No definitive conclusion could be derived on dose proportionality for q.d. doses on Day 1 and for Q12 doses on Day 14.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Steady state was achieved by Day 3 following q.d. and Q12 multiple doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Following multiple q.d. doses, accumulation ratios (R ac) based on C max and AUC0–tau showed no to minimal accumulation of ESK‐001 (mean R ac C max ranged from 0.71 to 1.41 and mean R ac AUC from 0.80 to 1.39).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Following multiple Q12 doses, there was an ~ 2‐fold accumulation of ESK‐001 (mean R ac C max ranged from 1.74 to 2.17 and mean R ac AUC from 1.74 to 2.42).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The C trough levels at the highest ESK‐001 dose of 40 mg Q12 were maintained above the in vitro human whole blood (HWB) 90% pSTAT inhibitory concentration (IC90) threshold (Figure 3c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Plasma pharmacokinetic parameters by multiple-dose cohort on days 1 and 14
Cohort and day (N = 6 per cohort)Cmax, ng/mLCtrough, ng/mLTmax, hAUC0–tau, h*ng/mLt½, hCL/F, L/hRac CmaxRac AUCtau
10 mg q.d. fasted, day 1“88.2 (42.7)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“2.02 (1.01–2.04)”View highlighted excerpt for this quote“630.8 (41.1)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote
10 mg q.d. fasted, day 14“99.5 (40.9)”View highlighted excerpt for this quote“11.8 (48.2)”View highlighted excerpt for this quote“1.60 (0.50–2.24)”View highlighted excerpt for this quote“795.8 (37.2)”View highlighted excerpt for this quote“9.22 (22.8)”View highlighted excerpt for this quote“12.6 (37.2)”View highlighted excerpt for this quote“1.13 (21.0)”View highlighted excerpt for this quote“1.26 (12.4)”View highlighted excerpt for this quote
20 mg q.d. fasted, day 1“171.4 (26.7)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“1.53 (0.51–2.07)”View highlighted excerpt for this quote“1338.0 (14.9)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote
20 mg q.d. fasted, day 14“132.0 (93.3)”View highlighted excerpt for this quote“15.1 (65.6)”View highlighted excerpt for this quote“2.10 (1.02–2.16)”View highlighted excerpt for this quote“1102.0 (71.4)”View highlighted excerpt for this quote“9.18 (36.7)”View highlighted excerpt for this quote“18.2 (71.4)”View highlighted excerpt for this quote“0.71 (80.2)”View highlighted excerpt for this quote“0.80 (79.9)”View highlighted excerpt for this quote
20 mg Q12 fasted, day 1“132.2 (20.9)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“2.01 (0.51–2.05)”View highlighted excerpt for this quote“793.1 (24.1)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote
20 mg Q12 fasted, day 14“287.1 (20.0)”View highlighted excerpt for this quote“108.7 (27.7)”View highlighted excerpt for this quote“2.06 (0.50–2.14)”View highlighted excerpt for this quote“1920.0 (17.3)”View highlighted excerpt for this quote“9.61 (7.6)”View highlighted excerpt for this quote“10.4 (17.3)”View highlighted excerpt for this quote“2.17 (32.7)”View highlighted excerpt for this quote“2.42 (25.6)”View highlighted excerpt for this quote
30 mg Q12 nonfasted, day 1“182.0 (46.6)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“2.09 (2.06–2.19)”View highlighted excerpt for this quote“1206.0 (38.7)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote
30 mg Q12 nonfasted, day 14“282.7 (24.0)”View highlighted excerpt for this quote“54.2 (306.4)”View highlighted excerpt for this quote“2.20 (2.12–4.19)”View highlighted excerpt for this quote“1878.0 (31.4)”View highlighted excerpt for this quote“7.60 (14.5)”View highlighted excerpt for this quote“16.0 (31.4)”View highlighted excerpt for this quote“1.74 (25.8)”View highlighted excerpt for this quote“1.74 (10.0)”View highlighted excerpt for this quote
60 mg q.d. nonfasted, day 1“356.7 (48.6)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“3.12 (1.13–4.07)”View highlighted excerpt for this quote“2934.0 (30.7)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote
60 mg q.d. nonfasted, day 14“503.8 (40.3)”View highlighted excerpt for this quote“45.5 (61.8)”View highlighted excerpt for this quote“2.09 (2.03–2.12)”View highlighted excerpt for this quote“4074.0 (33.7)”View highlighted excerpt for this quote“9.56 (20.2)”View highlighted excerpt for this quote“14.7 (33.7)”View highlighted excerpt for this quote“1.41 (34.4)”View highlighted excerpt for this quote“1.39 (30.5)”View highlighted excerpt for this quote
40 mg Q12 fasted, day 1“249.6 (25.9)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“2.06 (1.01–4.01)”View highlighted excerpt for this quote“1574.0 (25.4)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote
40 mg Q12 fasted, day 14“437.4 (49.0)”View highlighted excerpt for this quote“226.3 (31.3)”View highlighted excerpt for this quote“1.08 (1.04–2.13)”View highlighted excerpt for this quote“3246.0 (50.2)”View highlighted excerpt for this quote“12.41 (29.8)”View highlighted excerpt for this quote“12.3 (50.2)”View highlighted excerpt for this quote“1.75 (61.9)”View highlighted excerpt for this quote“2.06 (51.2)”View highlighted excerpt for this quote
Inhibition of IFNα-induced pSTAT1 in T cells by dose

“In the MD study, IFNα‐induced pSTAT1 expression was analyzed in T cells from whole blood as a measure of TYK2 inhibition and confirmed robust pharmacologic activity of ESK‐001 with a clear dose‐dependent effect (Figure 4a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Maximal TYK2 pathway inhibition was achieved within 2–4 h for all doses >10 mg q.d., with dose‐dependent differences observable at later timepoints following the last dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At the highest daily dose of 80 mg (administered as 40 mg Q12), maximal levels of TYK2 inhibition were achieved within 2–4 h and maintained throughout the Q12 dose interval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At the lowest total daily dose of 10 mg q.d., a partial TYK2 inhibition profile was achieved, with TYK2 inhibition peaking at <50% inhibition within 2–4 h and quickly returning to baseline TYK2 activity with minimal inhibition measured at 12 and 24 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All dose levels returned toward normal TYK2 activity 24–48 h after the last dose on Day 14.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events by multiple-dose cohort
Event10 mg q.d. fasted (N = 6)20 mg q.d. fasted (N = 6)20 mg Q12 fasted (N = 6)30 mg Q12 nonfasted (N = 6)60 mg q.d. nonfasted (N = 6)40 mg Q12 fasted (N = 6)Total active (N = 36)Pooled placebo (N = 13)
Participant with at least 1 TEAE“3 (50.0) [7]”View highlighted excerpt for this quote“5 (83.3) [11]”View highlighted excerpt for this quote“5 (83.3) [14]”View highlighted excerpt for this quote“5 (83.3) [10]”View highlighted excerpt for this quote“4 (66.7) [16]”View highlighted excerpt for this quote“5 (83.3) [14]”View highlighted excerpt for this quote“27 (75.0) [72]”View highlighted excerpt for this quote“11 (84.6) [19]”View highlighted excerpt for this quote
Mild“3 (50.0) [6]”View highlighted excerpt for this quote“5 (83.3) [10]”View highlighted excerpt for this quote“5 (83.3) [14]”View highlighted excerpt for this quote“5 (83.3) [9]”View highlighted excerpt for this quote“4 (66.7) [11]”View highlighted excerpt for this quote“5 (83.3) [14]”View highlighted excerpt for this quote“27 (75.0) [64]”View highlighted excerpt for this quote“11 (84.6) [18]”View highlighted excerpt for this quote
Moderate“1 (16.7) [1]”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“3 (50.0) [5]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“6 (16.7) [8]”View highlighted excerpt for this quote“1 (7.7) [1]”View highlighted excerpt for this quote
Severe“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAEs considered related to the study drug“1 (16.7) [2]”View highlighted excerpt for this quote“2 (33.3) [4]”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“3 (50.0) [3]”View highlighted excerpt for this quote“4 (66.7) [11]”View highlighted excerpt for this quote“4 (66.7) [8]”View highlighted excerpt for this quote“15 (41.7) [29]”View highlighted excerpt for this quote“1 (7.7) [1]”View highlighted excerpt for this quote
TEAEs leading to study drug discontinuation“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (2.8) [1]”View highlighted excerpt for this quote“1 (7.7) [1]”View highlighted excerpt for this quote
Any serious TEAE“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Erythema“2 (33.3) [2]”View highlighted excerpt for this quote“5 (83.3) [6]”View highlighted excerpt for this quote“5 (83.3) [5]”View highlighted excerpt for this quote“4 (66.7) [5]”View highlighted excerpt for this quote“2 (33.3) [2]”View highlighted excerpt for this quote“2 (33.3) [2]”View highlighted excerpt for this quote“20 (55.6) [22]”View highlighted excerpt for this quote“9 (69.2) [11]”View highlighted excerpt for this quote
Headache“0”View highlighted excerpt for this quote“3 (50.0) [5]”View highlighted excerpt for this quote“2 (33.3) [2]”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“4 (66.7) [9]”View highlighted excerpt for this quote“4 (66.7) [8]”View highlighted excerpt for this quote“14 (38.9) [25]”View highlighted excerpt for this quote“1 (7.7) [1]”View highlighted excerpt for this quote
Gastrointestinal disorders“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“2 (33.3) [2]”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“5 (13.9) [5]”View highlighted excerpt for this quote“1 (7.7) [1]”View highlighted excerpt for this quote
Psychiatric disorders“1 (16.7) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“2 (5.6) [2]”View highlighted excerpt for this quote“1 (7.7) [1]”View highlighted excerpt for this quote
Dysmenorrhoea“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (2.8) [1]”View highlighted excerpt for this quote“2 (15.4) [2]”View highlighted excerpt for this quote
Incidence, severity, relatedness, discontinuations, and laboratory findings in the multiple-dose study

“Thirty‐eight (77.6%) participants experienced 91 TEAEs; 27 (75.0%) participants receiving ESK‐001 experienced 72 TEAEs and 11 (84.6%) participants receiving placebo experienced 19 TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Most TEAEs (90.1%) were mild in severity; all other TEAEs were moderate in severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There was no dose‐dependent increase in the number of TEAEs or meaningful change in the severity levels observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The frequency of headaches appeared to increase with increasing dose of ESK‐001; however, most headaches (80.8%) were observed to be mild in severity across all dose levels and resolved without sequalae.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Two participants discontinued the study drug and study due to TEAEs; one participant receiving ESK‐001 (Cohort 30 mg Q12 nonfasted) due to rash morbilliform (considered study drug‐related), and one receiving placebo (Cohort 60 mg q.d. nonfasted) due to COVID‐19 (considered not study drug‐related); both TEAEs were mild in severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most common TEAEs (reported in ≥30% of the participants in any group) by preferred term were erythema and headache.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Events of erythema were secondary to skin taping for a sample collection procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fifteen (41.7%) participants receiving ESK‐001 experienced 29 TEAEs considered related to the study drug and 1 (7.7%) participant receiving a placebo experienced a TEAE considered related to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Minor fluctuations occurred in coagulation, clinical chemistry, and urinalysis parameters, but without treatment‐related trends.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Two participants reported an abnormal clinically meaningful laboratory value; one for Strep A2 rapid screen on Day 8, and one for SARS‐CoV‐2 RNA on Day 9.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Study limitations
Summary
  • The authors advise caution in interpreting the dose proportionality analysis because of the small number of participants, the limited q.d. and Q12 dose range, and the wide 95% CIs; no definitive conclusion could be derived for q.d. doses on Day 1 and Q12 doses on Day 14.
  • Participants were 49 healthy adults (36 envudeucitinib, 13 placebo) treated for 14 days at one site.
  • The last two cohorts (30 mg Q12 and 60 mg q.d.) were dosed nonfasted, while the other cohorts were dosed fasted.
  • The Sponsor was unblinded, and five placebo participants with unexpected ESK-001 plasma concentrations were excluded at the Sponsor's request.
  • Some pharmacodynamic samples were collected on Day 13 instead of Day 14, and urine was analyzed for only 3 of the 6 cohorts, with one outlier participant raising the 20 mg q.d. means.
  • Erythema, the most common TEAE with headache, was secondary to skin taping for a sample collection procedure.
  • The article describes a parallel-group study conducted from April 15, 2022 to September 20, 2022; the ClinicalTrials.gov record lists sequential assignment, a start on 2022-05-12, and completion on 2022-12-31, and reads “No Results Posted”.

Asian ethnic bridging study

Objective
Location and study date

No evidence found.

Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics by ethnic cohort
CharacteristicCohort 1: Japanese (n=8)Cohort 2: Chinese (n=8)Cohort 3: Caucasian (n=8)Overall (n=24)
Age (years), mean (SD)“42.6 (9.3)”“38.4 (8.2)”“45.5 (11.8)”“42.2 (9.9)”
Sex, female/male, n (%)“1 (12.5)/7 (87.5)”“0 (0.0)/8 (100.0)”“5 (62.5)/3 (37.5)”“6 (25.0)/18 (75.0)”
Hispanic or Latino, n (%)“0 (0.0)”“0 (0.0)”“2 (25.0)”“2 (8.3)”
Not Hispanic or Latino, n (%)“8 (100.0)”“8 (100.0)”“6 (75.0)”“22 (91.7)”
Height (cm), mean (SD)“170.2 (8.2)”“170.0 (3.0)”“168.6 (7.7)”“169.6 (6.4)”
Weight (kg), mean (SD)“66.4 (10.2)”“72.6 (9.7)”“80.4 (8.1)”“73.1 (10.7)”
Efficacy results
Steady-state pharmacokinetics of the parent drug and main metabolite on day 7 of 40 mg twice daily, by ethnic cohort
ParameterCohort 1: Japanese (n=8)Cohort 2: Chinese (n=8)Cohort 3: Caucasian (n=8)
Cmax,ss (ng/mL), geometric mean (CV%)“502 (25.1)”“586 (24.3)”“531 (11.1)”
AUC0-τ,ss (hr*ng/mL), geometric mean (CV%)“3,410 (22.7)”“4,580 (18.3)”“3,530 (9.5)”
Tmax,ss (hr), median (min, max)“2.8 (2.0, 4.0)”“3.0 (1.0, 6.0)”“1.0 (1.0, 2.0)”
t1/2,ss (hr), geometric mean (CV%)“7.6 (20.4)”“8.4 (13.4)”“9.1 (17.0)”
CL/F (L/hr), geometric mean (CV%)“10.8 (22.7)”“8.0 (18.3)”“10.4 (9.5)”
Vd/F (L), geometric mean (CV%)“118.0 (35.9)”“97.4 (26.5)”“138.0 (17.7)”
BWCmax (ng/mL/mg/kg), geometric mean (CV%)“895 (32.5)”“1,140 (14.3)”“1,140 (12.6)”
BWAUC0-τ,ss (hr*ng/mL/mg/kg), geometric mean (CV%)“6,080 (26.9)”“8,950 (9.8)”“7,540 (11.4)”
Rac, geometric mean (CV%)“2.10 (96.3)”“2.48 (38.0)”“2.09 (34.7)”
MRCmax main metabolite, geometric mean (CV%)“2.65 (33.6)”“2.91 (23.1)”“2.60 (24.9)”
MRAUC main metabolite, geometric mean (CV%)“3.56 (30.3)”“3.69 (24.9)”“3.73 (15.8)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events by dose period and ethnic cohort
Event20 mg, Japanese (n=8)20 mg, Chinese (n=8)40 mg, Japanese (n=8)40 mg, Chinese (n=8)40 mg BID, Japanese (n=8)40 mg BID, Chinese (n=8)40 mg BID, Caucasian (n=8)
Any TEAE, n (%)“1 (12.5)”“2 (25.0)”“5 (62.5)”“1 (12.5)”“4 (50.0)”“5 (62.5)”“6 (75.0)”
At least 1 TEAE Grade 2, n (%)“0 (0.0)”“1 (12.5)”“0 (0.0)”“1 (12.5)”“1 (12.5)”“0 (0.0)”“4 (50.0)”
At least 1 TEAE Grade ≥3, n (%)“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”
TEAE related to study medication“1 (12.5)”“1 (12.5)”“5 (62.5)”“1 (12.5)”“4 (50.0)”“4 (50.0)”“6 (75.0)”
TEAEs leading to study discontinuation“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“1 (12.5)”
TEAEs leading to study medication discontinuation“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“1 (12.5)”
Study limitations
Summary
  • The only source is one congress poster; no registry record, study location, or study dates are quoted, and the poster states no limitations.
  • The study was single-center and open-label, with 24 healthy participants (8 per cohort).
  • The Caucasian cohort received only 40 mg BID, and the Caucasian single-dose curves were plotted with data from another study (ESK-001-003).
  • Day 7 pharmacokinetic profiles of the twice-daily regimen were obtained in the fed state for the Japanese and Chinese cohorts and in the fasted state for the Caucasian cohort.
  • The cohorts differed in sex (female/male: 1/7, 0/8, and 5/3) and mean weight (66.4, 72.6, and 80.4 kg), and the results are descriptive statistics that are not log-transformed.

ESK-001-019

Objective
Location and study date
Recruitment and results status in the ClinicalTrials.gov record
FieldQuoted record
Overall status“Completed”
Results“No Results Posted”
Last update posted“2026-01-30”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using placebo-adjusted change in QTcF as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • The study is known only from its ClinicalTrials.gov record, which reads “No Results Posted”; the report holds no QTcF, ECG, pharmacokinetic, or safety result.
  • The record was first submitted on 2025-12-10, after the actual study completion date of 2024-08-31.
  • The record describes the therapeutic and supratherapeutic arms each as one oral dose of ESK-001 without stating the dose.
  • The study gave single doses to 52 healthy participants aged 18 to 55 years at one site, with the moxifloxacin positive control given open label.

ESK-001-022

Objective
Location and study date
Recruitment and results status in the ClinicalTrials.gov record
FieldQuoted record
Overall status“Completed”
Results“No Results Posted”
Last update posted“2026-05-12”
Study design
Eligibility criteria
Key inclusion and exclusion criteria in the ClinicalTrials.gov record
CriterionQuoted record
Inclusion, all participants“Body mass index between 18.0 and 40.0 kg/m2”
Inclusion, hepatic impairment“Diagnosis of chronic (> 6 months), stable hepatic impairment with no clinically significant changes within 30 days prior to dosing, as determined by medical history”
Exclusion, all participants“Uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 105 mmHg), or uncontrolled treated/untreated hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg), or resting pulse rate < 45 or > 100 bpm.”
Exclusion, healthy volunteers“Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.”
Exclusion, healthy volunteers“Positive hepatitis panel and/or positive human immunodeficiency virus test.”
Exclusion, hepatic impairment“History of any uncontrolled or unstable renal, hematological, gastrointestinal, neurological, endocrine, or psychiatric disorder, as determined by the investigator or designee, within 6 months prior to screening.”
Exclusion, hepatic impairment“History or current diagnosis of uncontrolled or significant cardiac disease indicative of a significant risk of safety for participation in the study.”
Exclusion, hepatic impairment“Liver function tests outside the appropriate reference ranges that are not consistent with hepatic dysfunction, as determined by the investigator or designee.”
Exclusion, hepatic impairment“QTcF > 480 ms for males or > 490 ms for females at screening or check-in, as confirmed from the mean of the original value and 2 repeats.”
Ages eligible for study“18 Years to 75 Years (Adult, Older Adult )”
Sexes eligible for study“All”
Accepts healthy volunteers“Yes”
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • The hepatic impairment study has no posted results, and the report holds no published results; its ClinicalTrials.gov record reads “No Results Posted”.
  • The design is open-label and non-randomized, with one dose of ESK-001 of unstated strength and a 48-hour outcome time frame.
  • Actual enrollment was 32 participants, against 48 estimated at registration and a planned structure of up to 24 healthy volunteers and 8 participants each with mild, moderate, and severe hepatic impairment; the number enrolled in each group is not reported.

ESK-001-023

Objective
Location and study date
Recruitment and results status in the ClinicalTrials.gov record
FieldQuoted record
Overall status“Completed”
Results“No Results Posted”
Last update posted“2025-12-10”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters and adverse event incidence as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • No pharmacokinetic or adverse event results of the renal impairment study have been posted, and the report holds no published results; its ClinicalTrials.gov record reads “No Results Posted”.
  • Only participants were masked, allocation was non-randomized, and each participant received a single dose with outcomes assessed over 48 hours.
  • Enrollment was 16 participants, against 48 estimated at registration, at four sites in Florida; the record plans 8 participants each with mild, moderate, and severe renal impairment but does not report how many were enrolled in each group, and participants requiring dialysis were not eligible.

ESK-001-002

Objective
Location and study date
Recruitment and results status in the ClinicalTrials.gov record
FieldQuoted record
Overall status“Completed”
Results“No Results Posted”
Last update posted“2023-05-09”
Study design
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
CriterionQuoted record
Inclusion: age and health“Healthy Men and woman age 18-60”
Inclusion: consent“Able to provide written informed consent”
Inclusion: pregnancy and lactation“Females can not be pregnant or lactating”
Exclusion: prior exposure“Prior exposure to ESK-001”
Exclusion: malignancy“History of malignancy within the last 10 years”
Exclusion: viral infection“Positive for HIV, Hepatitis B or C”
Exclusion: tuberculosis“History of tuberculosis”
Exclusion: alcohol or drugs“Positive test for alcohol or drugs”
Ages eligible for study“18 Years to 60 Years (Adult )”
Sexes eligible for study“All”
Accepts healthy volunteers“Yes”
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • The relative bioavailability, food effect, and gastric acid reduction comparisons (liquid, tablet fasted, tablet fed, and tablet with rabeprazole) have no posted results, and the report holds no published results; the ClinicalTrials.gov record reads “No Results Posted”.
  • The study was a single-center, open-label crossover study; the registered description calls it partly randomized and plans 15 healthy participants, and actual enrollment was 14.
  • Each participant received a single dose on 4 occasions, so the comparisons rest on single-dose pharmacokinetics in healthy adults aged 18 to 60 years.